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Abstract 
The objective of this study was to resuscitate isolated beating porcine hearts obtained 
from slaughterhouse swine for a minimum of 1 hour with a crystalloid buffer reperfusion 
instead of blood via an extracorporeal Langendorff apparatus. The isolated beating heart 
functions outside of the body under simulated physiologic conditions. Live functional 
anatomy was controlled under benchtop experimental settings. Porcine hearts (26 total) 
were topically cooled with saline. 300mL of 25⁰C cardioplegia with 20KU Streptokinase 
was preflushed via aortic root. WIT was less than 5 minutes.  1L 4⁰C cardioplegia was 
flushed antegrade with aortic cannula (Group 1) or coronary catheterization (Group 2). 
Each heart was kept in 4⁰C 1L modified Plegisol storage for >1 hour cold ischemic time 
prior to resuscitation. Hearts were submerged in 500mL of 15⁰C and 25⁰C Krebs 
Henseleit buffer prior to being mounted on the Langendorff apparatus. Hearts were 
resuscitated by 5L of 37⁰C oxygenated modified Krebs Hensleit buffer circulation. Low 
WIT, Streptokinase, and coronary catheterization resulted in 1 hour global contraction, 
and 110bpm stabilized sinus rhythm. ECG displayed prominent QRS complex.  
Significant calcium overload and edema inhibited contractile function at 1 hour. The 
Langendorff beating heart apparatus will serve as a platform for further biomedical 
engineering research to evaluate the efficacy of medical devices such as heart valves and 
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Chapter 1: Background 
1.1 Introduction 
Chapter 1 of the thesis consists of background knowledge to prepare the reader for the 
main study. The background section provides the anatomy and physiology foundation of 
the cardiovascular field, including coronary circulation and ionic physiology. The 
electromechanical ion gradient creates a voltage, resulting into the action potential. The 
background continues to widen the scope from the microcellular build-up, by 
summarizing how systemic action potential forms the electrical system of the heart. To 
monitor the cardioelectrophysiology of the natural in vivo heart, the reader will recognize 
the essentials of both regular and irregular ECG.  From in vivo conditions, the focus 
redirects to ex vivo conditions of an isolated heart, such as heart transplantation 
techniques. These techniques provide an understanding on how the isolated heart will be 
preserved and reanimated. The resuscitative Langendorff technique is introduced to the 
reader, including its two methods of perfusion—constant flow or constant pressure. As 
human hearts hold significant more importance for operable transplantation and thus 
were inaccessible for the study, a comparative summary between human and pig hearts is 
discussed; Pig hearts may substitute human hearts as donor hearts based on anatomy and 
function similarities. To validate reliability of hearts for the study, advantages and 
disadvantages of the three types of donor hearts are discussed, proceeding to the choice 




 The remainder of the thesis delves into key literature review, methods and materials 
for the experiment, results, and discussion. Chapter 2 constructs the requirements of the 
elementary procedure based on preliminary Langendorff studies. The various studies 
provide a wide spectrum of available buffers, donor hearts, pharmaceutical agents, 
temperatures, cost-efficiency and the corresponding results for the formation of the 
procedure. Two specific studies were analyzed in terms of the recovery of slaughterhouse 
porcine hearts and usage of crystalloid-perfusate instead of blood. Chapter 3 discusses 
material and methods for the procedure, including modifications to and stabilize global 
cardiac contractile function and increase the duration to <1 hour. Materials reviewed are 
cardioplegia, antithrombotic drugs, and the perfusion buffer, concluding with the 
finalized procedure. However, not all materials were kept for the finalized procedure. The 
developed procedure is categorized by slaughterhouse harvest, preservation, and 
reperfusion. Chapter 4 starts with a brief overview of all 13 experimental tests (Hearts 1-
26) in chronological order to visibly dictate the progress and modifications made, 
achieving the finalized procedure. The chapter is broken down to results for each test. 
Results follow a consistent structure starting with the simplified procedure, what 
variables were specifically studied that day, results of the experiment, and follow-up of 
what should be tested specifically for the following test. Confirming the finalized 
procedure, Chapter 5 centralizes on the discussion of hypothermic effect, and metabolic 
changes of the isolated heart.  Limitations that ceased the heart’s contractile function at 1 
hour such as calcium overload and edema are addressed. Chapter 6 concludes the study 
with a limelight on future directions the Langendorff apparatus may take. Future works 
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include the next step of a convertible Langendorff/four-chamber working heart system, 
and a mobile Langendorff apparatus, allowing potential collaboration. As the 
Langendorff apparatus can serve as a research platform, future directions will investigate 
research and development of medical devices, injuries, and therapies. There is definitive 
prospective for the Langendorff apparatus based on resuscitative devices aiding cardiac 
transplantation in the market today. The entirety of the report includes references in 
support of the text that may be closely viewed at the reader’s digression.  References are 
denoted numerically in superscript brackets.  
1.2  Cardiovascular Anatomy 
  In a natural working heart system found in mammalian species, venous deoxygenated 
blood enters from the superior and anterior vena cava which collects into the right atrium 
(RA) – the process known as atrial diastole or the relaxation-filling period. When the 
atria contracts, the atrial pressure exceeds the right ventricular (RV) pressure, forcing 
blood flow into the ventricle. This action is known as atrial systole/ventricular diastole. In 
ventricular systole, to avoid blood backflow towards the RA, the tricuspid valve shuts 
and pulmonary valve opens, allowing blood to expel towards the lungs for oxygenation 
via ventricular contraction. The pulmonary valve shuts to avoid backflow once pressure 




Figure 1.2.1 – Standard anatomy of the heart with deoxygenated blood from the 
systematic circulation on the right chambers and oxygenated blood from the pulmonary 
circulation 
[1] 
  Gas exchange occurs for blood at the lungs’ alveoli before entering to the left atria 
(LA) via pulmonary veins. Once again, atrial systole occurs when LA pressure exceeds 
left ventricle (LV), the act known as ventricle diastole. The mitral valve also known as 
the bicuspid or left atrioventricular valve between the LA and LV shuts; during LV 
systole, blood volume is ejected via aortic valve and backflow into LA is ceased. 
Subsequently, pressure in aorta exceeds LV and thus shuts the aortic valve. The force of 
the heart contraction expels blood to the systematic circulation, exiting out the aortic 
valve and to the rest of the body’s circulation.  Figure 1.2.1 summarizes blood flow 
activity as the heart functions as two pumps for two separate circulations—one 





1.3 Coronary Circulation    
  The blood supplies nutrients, gas exchange, proteins, vitamins, hormone, other 
metabolic substrates, and waste removal to and from every surface area of the body for 
continued mechanical and cellular activity. As it does so, the heart itself, and more 
specifically the myocardium, must also be supplied with blood as it would for any other 
organ. As mentioned in Section 1.2 pertaining to heart anatomy, the aortic valve shuts 
following ventricular diastole in the left ventricle. Roughly 5% of the cardiac output 
reroutes to the coronary ostia which maintain an average resting coronary blood flow at 
250 ml/min via systolic pressure of <120 mmHg
[2]
. The coronary ostia are openings 
located at the base of the aortic root immediately superior to the valve, and form the 
entrance of the right and left coronary artery. The right coronary artery (RCA) branches 
into the right marginal and posterior interventricular artery whereas the left coronary 
artery (LCA) diverges into the circumflex artery which in a way crowns and revolves 
near the posterior side of the atrium, as well as the anterior interventricular artery 
(otherwise known as left anterior descending artery). Pacemaker cells that initiate the 
heart rate are found in the sinoatrial (SA) node (further discussed in Section 1.5) and are 
supplied by either the RCA or LCA at a 60-40% rate in the general population. Like all 
other capillaries, oxygen is exchanged towards the tissue as carbon dioxide enters the 








  Deoxygenated venous blood collects at the coronary sinus found near the right 
atrioventricular junction and similar to other ostia, is mediated by the Thebesian valve to 
prevent backflow during Right Atrium systole. Blood from the sinus then empties into the 
right atrium along with systemic deoxygenated blood. The vasculature for coronary 
circulation can be viewed in Figure 1.3.1. Though pacemaker cells may initiate the 
electrical impulse of the heart rate, regulations are overridden by the SA node.  
1.4  Systemic Cardiovascular Physiology    
Cardiovascular mechanisms are regulated by the extrinsic and intrinsic responses, 
neuroendocrinic systems and autoregulation, respectively 
[4-8]
. The SA node is innervated 
by a branch of the Vagus nerve (Cranial Nerve X) called the Cardiac Plexus. A mixture 
of sympathetic (excitatory or stimulatory) and parasympathic (inhibitory) nerves from the 
involuntary Autonomic Nervous System make up the Cardiac Plexus. The innervation 
moderates the heart rate. Sympathetic nerve increases heart rate, blood pressure, 
myocardial contractility, cardiac output and vasodilates; Parasympathetic nerves enable 




cardiac output. Neurotransmitters that aid in the autonomic nervous regulation are 
norepinephrine, epinephrine, and acetylcholine. Postsynaptic myocardial receptors such 
as α2 adrenergic and M2 muscarinic receptors decrease cardiac output and contractility 
while β-adrenergic increases it [7]. Serotonin has complex effects on both stimulating and 
depressing cardiac functions 
[9]
. Drugs that are agonists or antagonist to the receptors will 
also affect cardiac function such caffeine and other stimulants to accelerate contractility 
or beta-blockers to decelerate contractility. Hormones that act as vasoconstrictors are 
vasopressin, angiotensin, and other catecholamines. Vasodilating hormones include 
corticotropin-releasing hormone and histamine. Reflex mechanisms include baroreceptors 
and chemoreceptors in the vessels, detecting levels of O2, CO2, and H
+ [4, 5]
. Endothelial-
derived nitric oxide also acts as a vasodilator in myocardial cells 
[10]
.  
The intrinsic cardiac regulations that meet local needs are independent of the rest of 
the body. If the organ were to be isolated, these mechanisms would continue to serve 
metabolic purpose.  Certain influential ion channels such as potassium, magnesium, and 
sodium allow vasodilation while open calcium channels enable vasoconstriction 
[11]
.  
 The Frank-Starling law allows the heart to change volumes of blood inflow. This law 
dictates that as the myocardial chambers stretch due to an increase in blood flow, a 
greater ventricular contractile force is required, increasing cardiac output 
[5, 6]
. For such a 
system to mechanically work, the cellular and ionic level must be understood.  
1.5  Ionic physiology 
  Electrical activity that enables spontaneous cardiac contractions can be attributed to a 
difference in the electrochemical gradient of the cells and thus are called cardiac action 
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potential. Classifications of these action potentials are dependent on the type of cells by 
which these potentials are produced from. Cardiac myocytes found in the atria and 
ventricles are present as the fast response action potential. As there is a fast response, 
there is a slow response, mitigated by the natural pacemaker cells found in the SA node. 
The ability for the action potential to occur resides in the cell membrane, specifically in 




), and calcium (Ca
2+
). 
These ions that allow resting and action potential to occur is what develops the electrical 
system of the heart.  
1.5.1 Ionic Influence on Resting Potential  
  The resting potential, or the resting state the cell naturally resides in, is based on the 
voltage difference across the cell membrane as seen in Table 1.1. At its resting state, 
cardiomyocyte, or excitable cells, is at -90 mV which holds similar for skeletal muscles. 
Extracellular voltage is at 0 mV while the difference in voltage in the cell itself changes, 
based on the difference in ionic concentrations.  
Table 1.1 – Average extracellular vs intracellular composition 
[12-14]














































In Table 1.1, extracellular solutions mimic blood while intracellular mimics the 
interior of the cell. Blood and similar solutions are high in sodium whereas the cell 





pumps to be driven via ATP usage to stabilize against the ionic diffusion.  
 




 at 2.5 mMol 
reflects calcium bound to protein along with ionized Ca
2+
. 
Table 1.2 – Equilibrium potential of core ions in cell. 
[5, 13, 14] 
Ion Equilibrium Potential 
Potassium -94 mV 
Sodium +67 mV 
Calcium +123 mV 
Chloride -86 mV 
The values found in Table 1.2 correspond with the specific single ion equilibrium 
charge. Thus, resting membrane potential is an aggregation of the concentration of ions 
within excitable cells. To sufficiently discuss how each ion plays a role in the cardiac 
action potential, certain transmembrane ionic channels and their properties must be taken 
10 
 
into effect as well as how the overall membrane potential is influenced by these channels 
as they selectively open and close.  
The primary transmembrane ionic channels are mostly voltage-gated in which the 




 ATPase pumps its 
respective ion against its gradient, the efflux of K
+
 diffuses outside the cell via leaky 
channels and inward-rectifier channels. Fast Na
+
 channels are voltage-gated, and thus are 
regulated at certain voltages. As fast Na
+
 approaches its equilibrium potential of +67 mV, 
the channel closes just as quick due to fast inactivation-gated periods.  
Long-lasting Ca
2+
 channels, or L-type calcium channels, stay open at a prolonged 
rate. Longer Ca
2+










to increase voltage of the membrane (depolarization) past a threshold with K
+
’s potential 
to decrease the voltage (repolarization) that creates the action potential.  
1.5.2 Action Potential 
The action potential is an electrochemical mechanism in which the resting membrane 
potential surpasses a threshold of -90 mV to depolarize, offsetting voltage-gated ion 
channels to open as ions pass through. The intracellular membrane potential is -94 mV 
due to K
+
 being the dominant ion enabling towards equilibrium, as referenced in Table 
1.2. Resting membrane potential leads the start of the cardiac action potential cycle. 
When the cell is at rest, K
+
 efflux occurs via K
+
 leaky channels, and membrane potential 
is slightly more positive than -90 mV, initiating Phase 0 and the onset of the action 
potential. With K
+
 diffusing out the cell, the membrane is slightly depolarized. At this 
11 
 
voltage, voltage-gated Fast Na
+
 channels open, with Na
+
 diffusing intracellularly.  Due to 
Na
+
 influx, membrane potential rapidly depolarizes, approaching Na
+
’s equilibrium 
potential of +67 mV but the Fast Na
+
 channel shuts at roughly 20 mV. On the verge of 
overshoot at 20 mV, voltage-gated K
+
 channels open, with efflux K
+
 movement. This in 
turn lowers the membrane voltage as K
+
 exits the cell and repolarization is inclined 
towards K
+
 membrane equilibrium at Phase 1. As it repolarizes and membrane potential 
is approximately +5 mV, Ca
2+
 now influences the cardiac action potential as Ca
2+
 
influxes via L-type channels. Ca
2+
’s resting potential is at roughly +120 mV, thus 
membrane potential is aimed towards depolarization. Meanwhile, additional slow-acting 
K
+
 channels open, increasing extracellular passage, aiming for repolarization. With the 
balance of K
+
 channels and Ca
2+
 channels concurrently open, their voltage effect balances 
and plateaus, as can be seen in Phase 2 of Figure 1.4.2. L-type calcium channels delay as 
they shut. By this point, inward-rectifier K
+
 voltage-gated channels continue to efflux, 
repolarizing towards -94 mV, meeting K
+
 equilibrium and resting membrane potential; 
thus, these channels too delay and close aside for the leaky channels. As the onset of 
action potential is based on the Fast Na+ channels, this specific action potential is a fast 
response action potential in cardiac muscle cells as opposed to a slow response action 
potential found in pacemaker cells of the heart. 
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Figure 1.5.2 – Fast response action potential of cardiac myocytes. 
[16]
 





aids in pumping Ca
2+
 in to the cell for reuptake by the sarcoplasmic reticulum, and in turn 
gets Na
+





-ATPase metabolic pump activate and restores equilibrium at resting 
potential, sending 3Na
+
 ions against its gradient extracellularly, and 2K
+
 ions 
intracellularly.  From Phase 0-3, effective refractory period (ERP) also takes place, in 
which the cell cannot be restimulated for arrhythmias to occur 
[5]
 . The benefit of ERP is 
to coordinate simultaneous contractions.  
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Figure 1.5.3 – Slow response action potential in autorhythmic cells. 
[17]
 
For slow response action potential which occurs strictly in pacemaker cells, resting 
membrane potential is -60 mV, allowing Na
+
 channels to open and Na
+
 to slowly influx, 
summarized in Figure 1.5.3. The cell is depolarized, meeting the threshold at -40 mV, 
which initiate Phase 0 similarly to fast response action potential shown in Figure 1.5.2. 
At this voltage, voltage-gated Ca
2+





becomes dominant, with the cell membrane rising and continues to depolarize towards 
Ca
2+
’s resting potential of +123 mV and then become gated at roughly +10 mV. While 
Na
+
 channels are still open, some positive-dependent voltage-gated K
+
 channels open as 
it permeates out. Membrane potential now inclines towards K
+
 and as K
+
 membrane 
equilibrium is -93mV, membrane potential repolarizes towards -90 mV. The K
+
 channels 
shut at -60 mV and the slow action potential is complete.  The derivation of which action 
potential is slow and fast is dependent on phase 0, or the onset of passing the threshold to 
the overshoot.  
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1.6 Electrocardiophysiology  
With the initiation of the slow action potential to produce an electrical impulse, this 
impulse spreads through the entirety of the heart through a sophisticated conduction 
system with the specialized excitable cells.  The monitoring of the conduction system of 
electrocardiograms or ECG in turn aids clinically to visualize offsets in certain chambers 
of the heart that undergo arrhythmias.  
1.6.1 Electrical conduction system 
  1% of cardiac cells are not myocytes but rather its gap junctions induce a conducting 
system 
[18]
. This conducting system initiating the sinus rhythm, or the electrical pathway 
that is then followed by contractions, starts from the SA node located in the right atrium, 
enabling the highest rate of depolarization across the magnitude of muscle cells. The SA 
nodal cells are the first order pacemaker cells. From there, the impulse travels via 
Bachmann’s bundle in which the impulse is carried towards the left atrium, as seen in 
Figure 1.5.1. Along with Bachmann’s bundle, the intermodal tracts conduction is carried 
towards the atrioventricular (AV) junction, rightfully called the AV node. Nodal 
conductions are inherently slower compared to conduction cells, leading for a 100 ms 
delay between not only the conduction between SA to AV but also atrial and ventricular 
contractility. The delay allows blood to move in coordinated flow based on two separate 
contractions either directing towards the lungs or the rest of the body
[18]
. 
The conducting tracts continue towards the Bundle of His, located in the 
interventricular septum which in turn splits into fascicles towards the left and right 
bundles of their respective ventricles. The bundles differentiate into Purkinje fibers 
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originating near the apex. The fibers allow global conduction through all ventricular 




Figure 1.6.1 – Electrical system of the heart. 
[18]
 
It is the variant action potentials of all different cardiac cells and activity—atrial 
diastole, atrial systole, ventricular diastole, ventricular systole—that can be graphed as a 
full unit per 1 heart contraction cycle seen in electrocardiographs (ECG). The ECG shows 
the propagation of depolarization as the action potential ultimately results in contractility. 
The SA node’s initial propagated atrial depolarization is seen as the P wave in ECG lead 
II and marks atrial contraction.  The QRS wave as seen in Figure 1.6.2 dictates 
ventricular depolarization as well as atrial repolarization and overall ventricular 
contraction. The T wave signifies ventricular repolarization. Ventricular contractions are 
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delayed and occur 0.1 second after atrial conduction  
[5]
. The ECG shown is an example 
of a normal sinus rhythm. 
Figure 1.6.2 – Depolarization propagated waves of both atrial and ventricular function 
are diagramed in ECG readings. SA node initiates the impulse for the atrial contraction to 
occur where the impulse passes through the intranodal tract to the AV node that then 
initiates ventricular contraction via depolarized waves of the myocytes contractions. 
[19]
 
1.6.2  Abnormal ECG readings 
 
ECGs can establish and chart the occurrence of a sinus rhythm base as well as types 
of arrhythmias dependent on certain waves that falter against the normal healthy heart. 
Figure 1.6.2 is an example of a normal sinus rhythm for one heartbeat. Arrhythmias that 
most impact an isolated heart are tachycardia and fibrillation, which may occur in both 
atrium and ventricles. Arrhythmias are detected in heart transplantation as the donor heart 
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is resuscitated  by blood prior to great vessel anastomosis and must be defibrillated to 
restart the sinus rhythm 
[20]
 .   
 
Figure 1.6.3 – Atrial fibrillation and flutter. 
[21] 
The atria may become irregular, resulting into atrial fibrillation (AFib) 
[5, 6, 22]
. AFib 
can result in heartrates of 400-600 bpm with poor blood flow. P waves won’t be seen in 
an ECG because the action potential are repetitively shooting, with very little crossing 
threshold.  As AFib is irregular, an atrial flutter is regularly irregular. An atrial flutter is 
similar to AFib but has a consistent yet increased heartbeat.  The flutter can be visualized 
by a sawtooth pattern on the P wave of short repetitive bumps not reaching peak, seen in 
Figure 1.6.3. Atrial flutters are approximately 250-350 bpm. Both atrial arrhythmias are 
also considered as supraventricular tachycardia.  
In general, ventricular tachycardia (VT) displays a widened QRS peak with ≥120 
seconds duration. If VT continues, ventricular fibrillation or sudden cardiac death can 
result. VT can result from an injury or block to the left bundle branch or right bundle 
branch found along the interventricular septum. Left bundle branch block VT has an 
elongated QRS peak with a downward bend while right bundle branch block displays an 
elongated QRS peak with an upward bend in the V1 ECG reading, as seen in Figure 





 (a)              (b) 




While ventricular tachycardia is stabilized rapid rhythm and originates at the 
ventricles with operable contractions, fibrillation has no order, displays irregular 
rhythmia and is a superficial twitch, with ineffective contractible activity. Similarly, the 
atria can undergo tachycardia, flutter, and fibrillation. The arrhythmia can lead to a series 
of complications including clots and risk for stroke; These disorders along with many 
cardiac diseases and cancers can lead to end-stage heart failure, where heart 
transplantations remains to be the only treatment.  
1.7  Heart Transplantation 
Since the discovery of human heart transplantation by Dr. Christiaan Barnard’s 
groundbreaking operation in 1967 utilizing Dr. Norman Shumway’s technique  
[25]
 to the 
proclamation of organ donation from brain-dead patients in 1981
[26]
, donor hearts have 
been widely used for heart transplants for those whose hearts are failing and incompetent 
to succeed in physiological body performance and circulation. By 1976 under the aid of 
the immunosuppressive therapy, heart rejection by the patient has significantly decreased, 





Heart transplantation can be seen as two stages: the retrieval of the donor heart and 
surgical operation for the transplant recipient 
[12, 28]
. Standard protocols for heart 
transplantation haven’t significantly changed overtime aside from anti-rejection 
medications for the heart. After matching criterions for legal brain death, the donor heart 
undergoes several screenings to match compatibility and prevent infectious transmission. 
Cold preservation solutions with high potassium concentration are used for diastolic 
arrest, during donor cardiectomy, and for transportation. Preservation solutions and 
similar heart transplant protocols will be investigated in Section 3.1 
[12, 27, 29-31].
 
The recipient is placed under anesthesia, with an incision made down the center of the 
chest; the sternum is divided to expose the heart. Blood flow is rerouted using a 
cardiopulmonary bypass machine so that the rest of the body has uninterrupted flow 
while vessels to the heart are clamped. The diseased heart is excised followed by the 
donor heart and vessels anastomosed, or reconnected. Clamps are removed to allow blood 
back into circulation via heart instead of the bypass machine. Defibrillation is used as 
needed as the cardiac functions of the new heart are carefully monitored. Excess fluids 
are drained; sternum is connected, followed by skin being stitched prior to sterile dressing 
[28]
.  
Although the population with diseases has increased across the decades, the number 
of transplantations performed is roughly stagnant. Figure 1.7.1 charts total 
transplantations performed in the United States since 1991, including patients on active 
waitlist and number of donors. Government statistics show that by the ending year of 
2013, less than a quarter of waitlisted patients had received a transplant.  Numbers of 
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transplants and organ recovery has stayed stagnant for the last decade with patients 
waiting for a life-saving transplant at a steady incline approximately at 4.1% 
[32]
. 18,048 
organ transplants have been performed between January to July 2015 
[32]
. As of 
November 2015, 122,620 Americans are on the waitlist, 79,228 of whom are active 
waiting candidates 
[32]
. 8,757 donors, both deceased and living, were recovered for the 
first 7 months of 2015. Compared to 121,272 waitlisted patients in 2013, there is clear 
indication of immobility. Heart transplants are <10% of overall procedures; there are 
currently 4,197 patients awaiting heart transplants. In 2014, 2,174 heart transplants were 
performed in the US from the total 29,532 general transplantations, with an additional 
>1,000 heart transplants done overseas 
[31-33]
. To reinstate, roughly 51% of those needing 
a life-saving heart will get one.  
 





Patients eligible for cardiac transplantation must have irreversible heart failure with 
age ranging between infantile to over age 65. There are slimmer chances of finding a 
matching heart for infants and growing children. For patients who have waited >4 months 
for a transplant in constant hospitalization with deteriorating conditions, the standard 
approach is that the patient uses a left-ventricular assist device. The device enables 
assistance for pumping blood in the patient’s body.   
With the lack of donor organs to provide viable treatments for waiting patients per 
year, there are slim chances for viable human hearts to be used for research instead of 
clinical implantations. As seen in the figure above, a global challenge is that the number 
of donor hearts available is less than patients seeking transplantation. Research in the 
cardiovascular field is progressing but is limited towards clinical tests and live animal 
models. The majority of human heart donors are prioritized for heart transplant rather 
than research, limiting the pool of hearts for research application. To expand the amount 
of available hearts, deceased isolated hearts can be of use if the heart is freshly preserved 
and then reanimated to beat. The Langendorff method shares many similarities to that of 
heart transplantation and moreover, the technique of preservation follows that of organ 
donor preservation for transplantation and clinical usage.  
1.8  Langendorff Perfusion 
 The Langendorff perfusion to reanimate the isolated mammalian heart was 
developed by Oscar Langendorff between 1895-1897 in Leipzig, Germany 
[34]
. The 
technique is largely used in society today on testing myocardial and coronary vasculature 
function, contractility, understanding cardiac diseases, injury brought upon by ischemia 
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or reperfusion, and leading up to the biotech industry of gene manipulation and protein 
expression. It has contributed advancements towards the electrophysiological, 
biochemical, and pharmacological fields. The advantage of using an isolated heart is that 
the central nervous autonomic system is eliminated by severing any neuronal 
coordination. Isolation of a heart offers both the advantage of separating intrinsic cardiac 
properties from extra cardiac regulating processes, and excellent accessibility to a wide 
variety of measuring techniques 
[13]
. Many studies imposed on an isolated heart cannot be 
reproduced utilizing an in vivo experiment without serious repercussions such as global 
ischemia, infarction, or cardiac arrest 
[35]
. The issues can be eliminated by optimal 
preservation.  For ideal protection, hypothermic cardioplegia is induced as the heart’s 
metabolism decreases along with oxygen usage.  
Langendorff method has the heart resuscitated and stabilized by reintroducing 
glucose, ions, and oxygenation into the coronary arteries to enable action potential in 
both the electrical system and cardiac myocytes. With all resuscitations, an efficiently-
working heart is one that has been well recovered, unstrained to injury or ischemia. The 
same mechanics from Section 1.3 on Coronary Circulation apply: As the pressure 
superior to the aortic valve increases and is more than pressure inside the left ventricle, 
the aortic valve shuts. Taking advantage of this cardiac physiomechanical property, the 
perfusate is redirected towards the left and right coronary ostia, leading to the respective 




Figure 1.8.1. – Anterior view of coronary ostia located in the aortic root. [36] 
After perfusion via arteries and capillaries, deoxygenated perfusate collects into the 
coronary sinus. Draining into the right atrium, the valve of Thespian (valve of coronary 
sinus) regulates the draining into the right atrium such as during atrial systole, that 
ejection of blood doesn’t regurgitated back towards the sinus. The Langendorff perfusion 
echoes what physiologically occurs in the in vivo heart, minus nervous attachment and 
endocrinal influences. As no internal activity occurs within the chambers, an 
intraventricular balloon is often inserted to enable an in-vivo matching pressurized 
contractility force 
[13]
. The balloon also enables parametric readings to distinguish global 
assessment of contractile function and pressure-volume relations.  
1.8.1  Constant Flow vs. Constant Pressure in Langendorff System    
 
Constant pressure and constant flow are two methods of delivering the perfusion to 
the heart using the Langendorff technique. Constant flow is utilized by a flow rate of 8-12 
mL/min/g wet tissue weight that is continuously perfused via peristaltic/roller pump 
[13, 14, 
35, 37-44]
. The constant flow regulated by the pump speed develops a dependent perfusion 
24 
 
pressure in which can be monitored by a pressure transducer that should range 80-120 
mmHg 
[5]
. However, compared to an increase of blood usage as work on the heart 
increases as it does in vivo, oxygen-dependent autoregulation is hampered. Even if the 
heart contractility performance increases or regional ischemia occurs, the flow rate is 
undetermined and is stagnant unless physically adjusted. Flow should be introduced 
directly into the coronary ostia via catheterization.   
Whereas constant flow prefers the ostia, coronary pressure advises that the flow is 
introduced from a cannula into the aortic root. The constant pressure is brought by a 
constant preload hydrostatic pressure which is influenced by placement and elevation of a 
compliance chamber. The importance of the chamber allows the physiologic pressure of 
80-120 mmHg 
[5]
.  Constant flow systems may determine perfusion pressure and vascular 
resistance. With constant pressure, coronary vascular tone is maintained and 
autoregulated with respect to change in resistance; constant flow may shear coronary 
vasculature under increased inotropic conditions 
[13, 42, 45]
.  The constant pressure method 
has its disadvantages; with too high pressure, greater risks of forcing the perfusion 
undermines edema onto the cell which in turn affects global cardiac tissue 
[46]
. The choice 
perfusion technique is dependent upon the resistance of coronary circulation. A system 
that harnesses both methods are optimal though enforces considerable effort. The 
Langendorff technique provides cardiac resuscitation; however, non-human hearts must 
be reviewed to serve as an efficient and reliable human model.  
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1.9  Pig and human comparisons 
  As described in Section 1.7, human donor hearts are prioritized for transplantation 
rather than research application and non-preserved human hearts offer very little as it 
cannot be resuscitated past necrosis. Porcine hearts can serve as an invaluable substitute. 
The porcine heart is of similar size, anatomy, and function and enlarges the heart 
candidates for testing such equipment and research, which is detailed in Table 1.3. 
Porcine hearts follow the classic Valentine shape, which can be explained due to broader 
apex with course trabeculations.  Human hearts are observed to be more trapezoidal.  
While the porcine LA has two pulmonary veins, human hearts have four. There are 
differences in appendages as the one superior to the porcine right atrium is more tubular 
on pig whereas the tubular appendage on a human is above the left atrium 
[47]
.  
Table 1.3 – Human and Pig physiological comparison 
[13, 14, 37, 47, 48]
 
 Adult human Adult pig 
Average weight (kg) 62-71 86 
Average heart weight (g) 250-300 358 
Resting heart rate (bpm) 60-100 100 - 150 
Average temperature (⁰C) 37 39 
 Pig coronary vasculature results in decreased total peripheral resistance and higher 
cardiac output, oncotic pressure than human 
[49]
.   Factors such as gravity that influences 
how the heart is situated in the body as well as pigs’ tissue aging at a quicker rate 
certainly play a role. Studies have shown that porcine blood is hypercoagulable due to its 
shortened partial thrombin time (PTT) compared to that of humans 
[50]
. In terms of action 
potential and heart rates, there are certain differences. P waves vary heavily, with the pig 
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  With respect to the musculature, porcine LV is much thicker compared to that of homo 
sapiens’ while the moderator band, myocardium specifically connecting a part of the AV 
right bundle towards the papillary muscles, is more superior 
[47]
. It is known as a 
moderator band as it aids in decreasing risk of ventricular overdistension. Due to the 
superior location found on the pig compared to human, right ventricular activation is 
further intensified, influencing contractility 
[50]
.  
Pig-to-human xenotransplantations have been attempted in the past, resulting into 
immediate death due to immunologic rejection of the transplant. Rejection can occur on a 
cellular level as hyperacute rejection. Hyperacute rejection results in inflammation, 
coagulation, fibrin deposits and platelet degranulation, hemorrhaging, and necrosis of the 
organ. However, if xenotransplantation succeed, the amount of heart donors would 
increase, eliminating shortage for patients with end-stage cardiac diseases. Current 
regenerative medicines are looking into pig embryos and stem cell application for 










The Merck Veterinary Manual, 10th edition. online version. Susan E. Aiello, 
ed. Copyright © 2015 by Merck & Co., Inc., Whitehouse Station, NJ. All 
rights reserved. Used with permission. Available at: 
www.MerckManuals.com. Accessed 3 Nov 2015 
Parameter Swine Human 
Albumin (g/dl) 1.8-3.4 3.5-5.2 
Ca 
2+
,total (mg/dl) 7.1-11.9 8.6-10.0 
Ca 
2+
, ionized (mg/dl) 3.5-5.8 4.4-5.3 
Cholesterol (mg/dl) 36-54 <200 
Creatinine (mg/dl) 1-2.7 0.65-1.2 
Glucose (mg/dl) 85-150 74-106 
Phosphate (mg/dl) 7.0-10.9 2.7-4.5 
TP (g/dl) 7.4-8.9 6.4-8.3 
Na
+
(mEq/l) 135-150 136-145 
K
+
(mEq/l) 4.4-6.7 3.5-5.1 
Cl
-
 (mEq/l) 94-106 98-107 
Mg
2+
 (mEq/l) 2.7-3.7 1.3-2.1 
Biochemical parameters of the serum for the two mammals fall within the same range, 
shown in Table 1.4. With the main differences pertaining to Albumin, cholesterol, 
creatinine, and Magnesium, a simple solution similar to blood plasma can be used to 
resuscitate both human and pig heart. As the porcine heart is verified to serve as a human 
model, advantages and disadvantages of the types of accessible hearts must be reviewed.   
1.10  Donor Heart Characterization for Isolated Porcine Heart Studies 
  Extracorporal hearts used for testings can be categorized in three ways: heart-beating 
donors, non-heart-beating donors, and slaughterhouse. For each category, the length of 
oxygen deficiency, or ischemia, must be taken into consideration. Warm ischemic time 
(WIT) is defined as the period from animal exsanguination and ends at cold preservation. 
Lesser WIT enables higher cardiac recovery and is recommended to be kept well below 5 
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minutes for minimal risk of ischemic injury 
[13, 14]
. There are dispute about the start of 
warm ischemia starting from organ excision rather than exsanguination 
[55]
. As there is 
WIT, there is cold ischemic time, though as the heart has cooled and metabolism is 
preserved, it is not as detrimental. Advantages and disadvantages will be discussed for 
each category of donor hearts.  
  Heart-beating donors are unconscious mammalian laboratory animals under anesthetic 
such as pentobarbital in which thoracotomy is performed and the heart is excised. 
Between animal research regulation and constant monitoring, usage of laboratory donors 
has high cost and heavy equipment usage. Long-term cases of pentabarbitol include 
impaired myocardial contractility. The advantages allow greater benefits than its 
shortcomings as it allows the facility with controlled experimentation. As the heart may 
take 3-5 minutes from excision to experiment reperfusion, its WIT is dramatically 
reduced. However, the institution did not have access to laboratory heart-beating donors.  
 Contrasting to beating animal donors, there are nonbeating heart donors. Nonbeating 
donors are defined as brain-dead cadavers with 25 minutes minimum WIT, having 
already undergone cardiac arrest. Advantages are that cadavers are easily accessible for 
other organ harvests and are a cheap alternative. However, necrosis and myocardial 
damage have already taken place on the tissue, allowing for poor resuscitation for the 
heart itself.  
 Slaughterhouse-harvested hearts are the third possible candidates, though the method 
is uncontrolled for the experiment. Under the United States Department of Agriculture 
(USDA) inspection for all lawfully-abiding livestock slaughter at abattoirs must comply 
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with food safety and humane handling laws. Contrary to anesthesia administration which 
is unlawful, brain death is commenced by either stunning or concussion. Though many 
slaughterhouses administer stunning and shocks, mechanical stunning determines brain-
death but allows systemic circulation to occur, and cardiac function is not compromised. 
An example of mechanical stunning is using a captive bolt pistol in which the skull is 
penetrated, cerebrum destroyed but brain stem intact for regulatory functions 
uninterrupted. The carotid artery is severed and the swine is ensanguined. Pericardium is 
inspected immediately after excision by a USDA officer for diseases. Advantages for 
slaughterhouse hearts are that the process is cost-effective. Disadvantages include 
uncontrolled settings as there is no access to the swine prior to USDA treatment. Also, as 
anesthetization is not allowed, pig stress levels are increased and thus stress hormones 
and neurotransmitters of certain catecholamine are increased. Compared to laboratory 
swine, slaughterhouse swine will have a faster HR. WIT will be greater than laboratory 
porcine hearts. Ischemia overall will lengthen by slaughterhouse location to the lab. 
However, WIT can be reduced by procedure, in which acting similarly to laboratory 





Chapter 2:  Preliminary Studies 
  The resuscitative technique produced by Oskar Langendorff in 1895 allows for in vitro 
hearts to continue beating after taken out of the animal’s body by reperfusion of an 
oxygenated warm nutrient-rich solution directed into the coronary arteries. Numerous 
studies have widely used this technique in observance for cardiac functions, diseases, 
pharmaceutical applications, myocardium necrosis, and other broad spectrum of the 
biology, chemistry, and medicine disciplines 
[12-14, 34, 39]
. Biomedical equipment design 
and development has also progressed due to the cost-efficiency of the Langendorff 
method and its easy access 
[13, 14, 29, 30, 35, 37, 38, 40-44, 46, 48, 56-76]
. In this chapter, preliminary 
studies were reviewed, which have constructed the foundations for the research in which 
assimilated the Langendorff procedure for this thesis. The following studies will discuss 
the laboratory animal used for heart reanimation, methods, and results. Most investigated 
studies had in vitro hearts resuscitated for >1 hour prior to working-heart conversion for 
approximately 4 hours
 [13, 14, 29, 35, 37-44, 48, 57, 58, 68, 70, 72, 73, 75-84]
. 
2.1  The Isolated Blood and Perfusion Fluid Perfused Heart 
Sutherland and Hearse 2000 
[35]
 developed a guide of the different methods to prepare 
isolated perfused hearts. The guide details on what types of studies can be tested using 
the Langendorff heart and discusses optimal usages for the following: mammalian hearts, 
temperatures, measurements and parameters, apparatus set-up, perfusion duration, buffer 
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composition, oxygen delivery. Options for the excision stage were explored: common 
advantages for small mammalian hearts such as rats, guinea pigs, mice, hamsters, and 
rabbits are that handling is easier and perfusion volume is smaller. Murine hearts are 
most frequently used but display the disadvantage of using a small heart by having small 
surface area and volume. Recording pressure measurements can be difficult with the 
small organ. Action potentials are indefinitely smaller than that compared to a large 
mammal, leading to high heart rates (HR). For example, an in vitro rat HR is 250-320 
bpm 
[35]
.  The advantage for large mammalian hearts is that results follow similarly to 
human physiologic rates as anatomy is similar. However, there is an increase in variables 
to monitor, resulting in high cost, more equipment, and a larger volume of perfusion 
buffer used.   With larger mammalian hearts, pressure recordings are easier to trace and 
differentiate from noise though some are heavily affected and functionally depressed due 
to anesthesia compared to others. The guide reviews types of inhalation agents, dosage, 
and application for certain animals. Different approaches for heart excision is discussed 
and brought to light and careful consideration of correct heparin dosage should be applied 
for intravenous-applied anesthetized animals.  
Reanimation stage discusses asanguinous and blood-perfused buffers and respective 
advantages, apparatus set-up, procedure. This study suggests that pure crystalloid 
perfusate be directed at 8-12 mL/min/g 
[35]
 of wet tissue weight whereas blood flow 
should be 3-4 mL/min/g tissue weight. Saline solutions may replace blood with regards to 
similar ionic levels. Crystalloid buffers have low oxygen carrying capacity unlike 





 compared to the blood alternative of 80-120mmHg 
[35]
 and is 
compensated in coronary flow rate. Though most studies choose one perfusion method 
over the other of constant pressure vs. constant flow, a convertible set-up between the 
two modes is most beneficial; however, a convertible set-up is not always feasible. Types 
of different aortic root cannula are covered, transitioning over to the set-up of the 
Langendorff equipment including water-jacketed reservoir with sintered glass oxygenator 
in which gas is distributed evenly to lower risk of air emboli within the coronary 
vasculature. Sutherland and Hearse recommend that a recirculated perfusate uses a 5 µm 
porosity filter. Pacing of hearts is left to the experimenter, with full regards to the 
knowledge that autorhythmicity is aided and augmented. If pacemakers are to be used, a 
bipolar stimulator should be chosen to lower the risk of electrolysis from the perfusion 
fluid and that position of the lead should be on the ventricle and while the reference 
electrode is on the cannula within the aorta.  However, because the SA node is perfused 
by vessels outside of coronary perfusion, it is a necessary element to be taken.  
  Optimal cardiac function requires an inflexible 37-37.5⁰C myocardial temperature. 
Nonetheless, hypothermia is preferred to hyperthermia as temperatures above 39⁰C will 
cause tissue injury. With the heart in isolated conditions, contractility deterioration occurs 
at 5-10%/hour though is influenced by preservation via static storage or continuous 
perfusion. When describing the best perfusion fluid, Sutherland and Hearse explain that 
the CaCl
2
 amount of 2.5 mMol is theoretically wrong despite matching physiological 
levels. In the blood, Ca
2+
 is bound to protein; plasma carries the ionized Ca
2+
 which is 
half the amount of 2.5 mMol and thus in the past, twice the amount of carbon chloride 
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has always been used when using non-protein related buffers. With these findings 
brought to light, ionized calcium concentrations are now brought to 1.2 – 2 mMol 
[35]
 in 
most isolated heart studies. Calcium should be last to be added to the buffer as it may 
precipitate, forming bonds with phosphate, heightening risk for coronary occlusions. 
Ways these occlusions can be disrupted is by adding carbogen before calcium addition. 
High addition of glucose at a near diabetic rate of 11 mMol 
[35]
  is utilized as to 
compensate for the lack of fatty acids. Fatty acids are first priority when harnessed for 
energy consumption in vivo though insulin may also be added. Though physiologically 
sought as the predominant energy consumption, fatty acids should not be used in 
crystalloid buffers as dissolving is limited and adds to frothing and foam creation when 
certain proteins undergo direct oxygenation. Whether to add non-dissolvable oncotic 
agents such as albumin or mannitol lowering the risk of edema and increase in global 
contractile function is at the experimenter’s discretion. 
The notion of bacterial or particles contamination should not be eliminated as it could 
develop and culture in the equipment itself if not properly sterilized in an autoclave. The 
risk can be eliminated by making fresh buffer the day of the experiment and not storing 
buffers with glucose or calcium titrated in an aqueous solution past 48 hours without 
vacuum filtration. It is not necessary to use antibiotics in the solution. Such equipment 
care will enable apparatus usage for multiple years. The last section of the report goes 






2.2  The Visible Heart Lab 
 The focus on the following studies narrows specifically on large mammalian hearts. 
The collaborative effort between University of Minnesota and Medtronic, the Visible 
Heart Lab, has designed one of the most highly developed and elaborate isolated heart 
platforms on a massive research and educational scale. In Chinchoy  et al. 2000 
[37]
 , 
beating swine donors were used. Once anesthetized and heparinized (10,000-30,000 U), a 
sternotomy was performed. The cardioprotective extracellular cold buffer St. Thomas 
Hospital solution #2 (Plegisol) with 25 mg adenosine mechanically arrested the heart via 
retrograde flow which was applied into the aorta with topical saline and ice induced. 
After excision, the hearts were placed in an ice and saline slurry mixture and transported 
for 5 minutes and attached to the Langendorff set-up for 40 minutes with continuous 
perfusion of a crystalloid buffer. Length of time between cardioplegic applications to 
reperfusion was averaged 74 minutes, with all hearts resuscitated and converted to 
working-heart mode. A clear oxygenated crystalloid 37⁰C solution of modified Krebs-
Hensleit buffer (KHB) was utilized instead of blood for camera probes and visual activity 
of the flow and physical intracardiac function. Additives to the KHB was chelating agent 
EDTA (0.32 mMol/L), insulin (10 U/L), sodium pyruvate to serve as fatty-acids for 
energy utilization (2.27 mMol/L), and mannitol (16 mM/L) to decrease swelling as 
perfusion pressure was set to 65 mmHg. The perfusion was requisite for spontaneous 
conduction and contraction. This specific preparation led to4 hours of global contraction 
as well as hemodynamic measurements near in vivo values. Pacing and defibrillator was 
as needed as the hearts beat spontaneously until autorhythmicity was stabilized. In the 
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Visible Heart Lab studies, dobutamine was used to manipulate hemodynamic 
characteristics to reach in vivo conditions, though lidocaine and epinephrine can be used 
as a substitute. Though edema progressed throughout the in vitro testing, cardiac 
performance was near stabilized even at 4 hours 
[37]
.  
  Continuing investigations in the Visible Heart Lab, Alexander Hill and colleagues in 
2005
[48]
 compared in vitro human hearts to the previous in vitro porcine hearts from 
2000
[37]
. Hearts obtained from human cadavers were not all diseased-free. Again, 
Langendorff perfusion was situated first to enable cardiac resuscitation and autorhymicity 
stabilization by constant flow before converting to working heart mode. Plegisol was 
used as cardioplegia, directed into the aortic root cannula above 100 mmHg with the 
heart topically cooled by ice. Storage solutions were cold saline or UW solution during 
transport, with the container placed in ice. At the lab, hearts were placed in ice slurry of 
modified KHB as the vessels were cannulated. 7L of 37⁰C modified KHB was used as 
reperfusate, with 4L replaced throughout the reperfusion for clear quality of transparency 
for visual activity, disposing catabolites. Buffer was shown to be warmed at location 17 
in Figure 2.1.1. Water jackets were maintained at 40⁰C, keeping perfusion at 37⁰C. 
Despite the non-usage of blood, a filter was used to separate large particles from the 
circulating KHB (5 and 10 in Figure 2.2.1). Defibrillation was used as needed for 
stabilization at 34J with the electrode placed on the exterior left ventricle epicardium. It 
was recommended that inotropic support be used before each defibrillating shock 
administered, such as epinephrine or dobutamine at the respected amount of 0.5 mg/mL 
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and 0.1 mg/mL. Systolic pressures were applied at 70-90 mmHg throughout the 4 hours 
of testing.  
 
Figure 2.2.1 – Langendorff schematic of the Visible Heart Lab apparatus pertaining 
human hearts 
[48]
. Reprinted with permission by Elsevier – (license number 
3677490412112). 
Locations 1-4 in Figure 2.1.1 of the Visible Heart apparatus are preload and afterload 
columns to enforce systemic and pulmonary circulation. Centrifugal pumps are located in 
7 and 8. Cannulation was at 18, 19, 22, and 23 of the pulmonary vessels, vena cava, and 
aorta while camera ports are located at 20 and 21. The divider at location 11 was what 






2.3  Eindhoven University of Technology 
Eindhoven University of Technology utilized slaughterhouse pig hearts instead of an 
animal-donor lab in 2005 
[13, 14]
. Hearts obtained from a slaughterhouse led to less control 
over the specific factors contributing towards the pigs’ death such as WIT.  Pigs obtained 
were of weights 90-100 kg and stunned by electroshock while blood was collected as 
perfusate mixed with 2500U heparin. Porcine hearts were excised and flushed by 1L 
modified Plegisol applied in retrograde fashion via aortic root. Warm and cold ischemic 
time were 5 minutes and 70-90 minutes, respectively; for optimal preservation, WIT was 
kept within or under five minutes. Hearts were transported in 1L STHS at 4⁰C immersed 
within an ice slurry transport bag. KHB was used as warm wash before reanimation at the 
lab with the addition of mannitol in the 37⁰C blood-KHB mixed reperfusion buffer which 
increased colloid-osmotic pressure.  3L of the recirculating blood reperfusion (25% 
hematocrit) was stored in a reservoir and transported by a centrifugal pump, passing 
through a membrane oxygenator that enabled radial blood flow 
[13]
.  Along with carbogen 
induced into the perfusate (95% oxygen, 5% carbon dioxide), the Langendorff circulation 
system utilized a filter to remove white blood cells before oxygenation as to not damage 
the cardiac muscle, as seen in Figure 2.3.1. Perfusion rate was set at a constant flow of 1 
mL/min/g tissue 
[35]
. Defibrillator was as needed, with shocks administered at 50, 70, or 
100 J; once stabilized with pacemaker application of 100-120 bpm, Langendorff hearts 
were assessed at 1, 2, 3, and 4 hours before transitioning to working ejecting mode. 
Pressure measurements were induced by pressure transducers connected to a fluid-filled 
latex balloon in the left atrium, as seen in the schematic. By hour 4, developed pressures 
38 
 
and heart rates deteriorated. One of the pilot studies for the thesis had KHB reperfusion 




Figure 2.3.1 – HemoLab 2005 Langendorff schematic. 
[13]
 
Schampaert et al. also of HemoLab, Eindhoven University of Technology developed 
a study in 2013 using slaughterhouse pigs 
[43]
. Heart weights averaged 472± 51 g. After 
electrocution, a sternotomy was performed and the heart was excised where it was then 
rapidly cooled by 1L Plegisol with the addition of 5000U heparin. Heparin application in 
cardioplegia was the first study found in literature review that did not have heparin added 
to the animal’s circulation itself. As before, WIT was within 5 minutes while 1L Plegisol 
was administrated hourly. Oxygenated 37⁰C blood was perfused [43]. Beating pig hearts 
mimicked in vivo flow and pressure. HR ranged 70-120 bpm, averaged 70 mmHg for 
coronary perfusion pressure and 0.7L/min coronary flow. As the aim of the study was 
autoregulation with regards to brief occlusion, length of reanimation time was not 
focused on.  
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2.4   Additional studies 
Grosse-Siestrup et al. 2002 study 
[38]
 highlighted the usage and non-sacrificial 
advantages of using slaughtered pigs. Out of the total 492 organs harvested, 191 were 
hearts. In addition to the organs, 1500L of autologous donor blood was collected and 
used for perfusion, with pigs slaughtered consecutively. Hearts were excised and 
cannulated within 6-7 minutes WIT prior to remaining organ harvest. Placed on ice, 500 
mL of cardioplegia was flushed prior to 500 mL of cold modified KHB flush. Modified 
KHB contained insulin and buadione monoxime additive were perfused via aortic 
retrograde infusion. Hearts were stored at 4⁰C during transportation. Altogether, standard 
procedures for hearts took 12 minutes, with heart excision prioritized compared to other 
organs harvested for the same lab. Autologous blood contained sodium citrate and 
10,000U/L heparin. Unfortunately, results were not annotated in the study as the 
emphasis was on abattoir porcine organs to benefit and improve the field of 
transplantation techniques and research 
[38]
.  
Petrucci Jr et al. 2003
[85]
 developed a study in which explanted a porcine heart was 
perfused by a parabiotic circulation using another anesthetized swine’s blood and body as 
seen in Figure 2.4.1. Mean donor weight was 22 kg. The animal donor that supplied the 
isolated heart was heparinized (500 IU/kg) as the heart was excised. WIT was 
approximately 14 minutes. The constant perfusion set-up was similar to the University of 
Minnesota apparatus in which blood was collected in a reservoir that was rewarmed at 
37⁰C, oxygenated, and pumped into the coronary arteries. The support animal was 
anesthetized by IV injection of fentanyl (12.5 µg/kg), pentobarbital (15 mg/kg), 
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pancuronium bromide (8 mg) as well as heparin. Jugular and carotid vasculature were 
cannulated. Onset of Vfib led to defibrillating shocks at 5 J. At 30 minutes, hearts were 
induced with regional ischemia and by global ischemia at 90 minutes along with 
reperfusion. Atrial pacemakers were used at 160 bpm for stimulation. Hematocrit of the 
perfused blood averaged 31.30 ± 3.40% while oxygen pressure was consistent at ≤ 300 
mmHg. Systolic pressure was 131.70 ± 6.4 mmHg for the first 60 minutes and decreased 
to 100.70 ± 9.62 mmHg.  
 
Figure 2.4.1 – Perfusion system of Petrucci Jr’s 2003 study in a parabiotic model. Heart 
explanted and blood circulating through the support animal. 
[85]
 
This study sheds light on the Gregg phenomenon or the Anrep effect—in which the 
rate of change in coronary perfusion results in a change in myocardial contractility and 
oxygen reuptake consumption 
[86]
. With the parabolic circulation, fatty acids increase in 
the blood, following results close to clinical settings, increasing metabolism 
[85]
.   
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M.A. Schechter et al. 2014
[80]
 created a similar apparatus to previous studies that 
included a centrifugal pump, bubble trap, and heating apparatus. Red blood cells were 
reconstituted in saline resulting in 20-25% hematocrit. An advantage to this study were 
calcium level details: Ca
2+
 was initially kept low at 0.3-0.5 mM/L prior to heart mounting 
via aortic cannulation with slow trickle flow to rid the system of air. The system steadily 
had reperfusion warmed to 37⁰C while the heart was attached and calcium added to the 
reperfusion. By stabilization and global contractile function, ionic Ca
2+
 was ≥0.8 mM/L 
[80]
. Aortic pressure ranged 40-42 mmHg, with fluctuations resulting from coronary 
resistance.  The preload chamber seen in Figure 2.4.2 was used in working-heart system 
and not Langendorff. The centrifugal pump allowed for control over pressure though 
transition between constant flow and pressure were employed.  The heart was 






Figure 2.4.2 – Apparatus schematic of M.A. Schechter 2014 study with red blood 
cell reconstituted by saline 
[80]
. Reprint under Creative Commons Attribution-
NonCommercial License. 
  Though University of Denver does not have immediate access to lab donor animals 
with monitored aesthesia and the equipment for excisions, the crystalloid salt reperfusion 
was a beneficial finding from the University of Minnesota studies due to its transparency. 
Key features taken from HemoLab 
[13, 14]
 was that slaughterhouse pigs can be utilized as 
well as anticoagulant could be administered into the cardioplegia instead of the donor 
animal’s circulation. Both Visible Heart Lab and HemoLab studies laid foundation to the 
research of this thesis, with specific investigation of additional literature 
[3, 5, 6, 8, 11-14, 27-30, 
35, 37-44, 46-48, 50, 55-68, 70-78, 81-85, 87-109]
. However, not all details could be found in literature 
due to proprietary license and thus had to be investigated to design and develop an 
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efficient Langendorff apparatus that allowed stabilized sinus rhythm for ≥1 hour and 








Chapter 3: Materials and Methods 
  Over the course of the two year research period, modifications provided a near-
consistent protocol to improve and increase global cardiac activity and preservation of 
porcine heart obtained from a slaughterhouse. The protocol entails the details of 
myocardial preservation, transportation, and reperfusion. Materials are explored, signified 
by cardioplegia (Section 3.1), Pharmaceutical antithrombotic drugs (Section 3.2), and 
Krebs-Henseleit buffer (Section 3.3). Based on types of solutions and agents available, 
Section 3.4 discusses the procedure detailed in part by 3 stages: Slaughterhouse harvest, 
preservation, and resuscitation at the laboratory.   
3.1  Cardioplegia 
  The application of cardioplegia is to induce rapid cessation of electrical activity, 
mechanical arrest, and paralysis of the heart 
[12]
. Cardioplegia is a generally hyperkalemic 
crystalloid solution above the physiologic level of 4 mMol K
+
, which enables 
depolarization. As referred to in Section 1.5, resting membrane potential for the myocytes 
is -90 mV via fast response action potential. Due to depolarization and Na
+
 influx, one 
last contraction occurs. However, K
+
 efflux ceases as its concentration gradient is higher 
extracellularly and no longer diffuses out. Sarcoplasmic reticulum Ca
2+
 reuptake occurs 
in the cell. Instead of the physiologic extracellular 4 mMol/L, cardioplegia involves 16 -
125 mMol/L of potassium 
[89]
. As membrane voltage threshold has been crossed at -60 
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mV, cardiac fibers are prevented to stimulate. As the resting membrane potential nears -
50 mV, Na
+
 channels inactivate due to cellular diastole. Global diastole prevents ATP 
utilization. It is pertinent that the solution is customized specifically to the organ being 
preserved. Despite ischemia, blood-based or crystalloid-based cardioplegic buffer 
application provides cellular protection. Optimal preservation utilizes cardioplegia along 
with hypothermia to restore as much as 80% ±17% cardiac function 
[30]
. The cardioplegic 
solution washes out metabolic waste (catabolites) such as free hydrogen ions, lactate, and 
any byproducts of anaerobic activity.  
Cardioplegia is categorized between two classes: extracellular and intracellular 
buffers, as charted in Table 3.1. Extracellular hyperkalemic solutions mimic the 
extracellular physiological fluid such as blood and plasma and thus are high in sodium 
whereas intracellular solutions are similar to the ionic concentration of a cell and high in 
potassium 
[12]
. The extracellular concept however is relative as K
+
 concentration remains 
high with respect to average physiologic K
+
 concentrations. 
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Disadvantages in extracellular solutions include inducing edema 
[6]
. Intracellular 
fluids enable rapid cardiac arrest and include lower risks of edema, preventing ionic 
toxicity during hypothermia. Based on these benefits, many studies favor intracellular 
preservation solution compared to extracellular
[29, 61, 77, 79, 84, 90, 108]
. However, intracellular 
fluids can initiate endothelial damage 
[110]
.  
 The solution may be applied in antegrade or retrograde perfusion. Antegrade flow 
follows in vivo circulation while retrograde is done against the natural order of flow. 
Flow from the coronary ostia to the coronary arteries or blood flow from the aorta to the 
systemic circulation is considered antegrade. An example of retrograde is to introduce 
flow from the coronary sinus to the cardiac veins. It should be taken into consideration 
that the flow direction is with respect to the vessel; retrograde flow can be induced 
towards the aortic root, but antegrade in the coronary arteries. Some studies perform a 
retrograde perfusion, using catheters past the right atrium and into the coronary sinus. 
Though long debated, antegrade flow is preferred though increased washout is supplied 
by administering both antegrade and retrograde flow. The additional flow secures 
washout of metabolites and contact with cardioplegia. To not entail tissue damage due to 
high pressure, perfusion should stay set at 120 – 140 mmHg for all solutions, whether for 




Static storage is a one-time application of the solution while continuous cardioplegia 
consistently circulates through coronary vasculature. The classic cold ischemic storage 
preserves hearts for 4-6 hours 
[41]
. Compared to continuous flow, static storage is easily 
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manageable with no operational equipment needed. Dependent on the storage for heart 
preservation, continuous cold perfusion enables greater recovery for the heart rather than 
static ischemic storage 
[111]
. Jahania et al. 
[12]
 promotes continuous cold perfusion in 
which 93% Left Ventricular End-Diastolic Pressure (LVEDP) was recovered in rabbit 
hearts after 24 hours of continuous perfusion using modified UW as compared to 35% 
LVEDP with static storage. Several literatures have compared not just the effects of static 
versus continuous application but also warm and cold-blood cardioplegia against 
crystalloid cardioplegia 
[11, 29, 61, 84, 111, 112]
. Continuous warm-blood cardioplegia provides 
higher recovery of left ventricular global contractile function and higher sarcoplasmic 
reticulum reuptake of intracellular Ca
2+
compared to its static cold counterpart 
[111]
. The 
reuptake of intracellular Ca
2+
 ceases edema. Other reports state that non-depolarizing 
cardioplegia provide optimal recovery of ventricular function such as cardioplegic HTK 
compared to Celsior, both extracellular solutions 
[78]
. The method for non-depolarizing 
cardioplegia is attributed by ceasing Na
+
 influx as well as removing extracellular Ca
2+
 to 
decrease contractile function 
[113]
. The main cardioplegia reviewed was the extracellular 
St. Thomas Hospital #2 solution and intracellular University of Wisconsin solution.  
3.1.1  St. Thomas Hospital Solution #2 (Plegisol™) 
In this thesis, St. Thomas Hospital solution #2 (STHS) is referred by the specific 
brand-name, Plegisol 
[89]
. Manufactured by Hospira Inc., the hyperkalemic extracellular 
solution mechanically arrests the heart, with Magnesium addition so that calcium 
overload risk are decreased, as seen in Table 3.2
[89] 
. Similar to saline ionic concentration, 
Plegisol is cost-effective and highly used in clinical and laboratory settings 




. However, sterilized pH is 3.8 and must be adjusted to pH 7.4 modified by 8.4% 
sodium bicarbonate in 10 mL aqueous solution. 
Table 3.2 – Composition of St. Thomas Hospital Solution #2 (Plegisol) 
[89] 
Active Ingredient/Active Moiety (g/L) 
Ingredient Name Strength (g/L) 
Potassium Chloride (Potassium Cation and Chloride ion) 1.193 
Sodium Chloride (Sodium cation and chloride ion) 6.43 
Calcium Chloride (Calcium cation and Chloride ion) 0.176 
Magnesium Chloride (Magnesium cation and Chloride ion) 3.253 
Inactive Ingredients 
Ingredient Name Strength 
Hydrochloric Acid  
Sodium Hydroxide  
Water q.s. 
3.1.2  University of Wisconsin (Viaspan) solution 
Manufactured by Organ Recovery Systems and also known as SPS-1 (Static 
Preservation Solution) or Belzer UW solution, the solution was developed by Drs. F.O. 
Belzer and J. Southard at the eponymous university 
[114, 115]
. UW solution is not suited for 
continuous coronary perfusion due to its viscosity enabling vasoconstrictuion and 
endothelial damage 
[110]
. However, it is most effective for static storage, leading to 80-
85% recovery based on several studies 
[99]
. High pressure flow of 120mmHg is 
recommended to compensate for vasoconstriction 
[110]
. Mohara et al 2002 had dog hearts 









Table 3.3 – Composition of Static Preservation Solution (SPS-1) UW Solution 
[99]
  
SPS-1 Static Preservation Solution (UW Solution) Composition (g/L) 
Pentafraction 50 
Lactobionic Acid (as Lactone) 35.83 
Potassium Phosphate monobasic 3.4 
Magnesium Sulfate heptahydrate 1.23 
Raffinose pentahydrate 17.83 
Adenosine 1.34 
Allopurinol 0.136 
Total Glutathione 0.922 
Potassium Hydroxide 5.61 
Sodium Hydroxide/Hydrochloric Acid Adjust to pH 7.4 
Water for Injection q.s 
 Based on Table 3.3, varied additives enable cardiac arrest, protection, and slow 
metabolism. Lactobionic acid and pentafraction offer osmotic support, and decreases 
edema. Potassium phosphate monobasic serves as the potassium source. While 
Magnesium sulfate heptahydrate is a desiccant, raffinose pentahydrate enables the 
hypertonicity for cell desiccation to occur before cooling. Adenosine reduces ATP 
catabolic rate, inhibits platelet aggregation and inflammatory cells, decreasing 
superoxides, and increases contractility 
[99]
, recovering developed pressure 
[13, 42]
. 
Allopurinol lowers uric acid in blood plasma. Glutathione reduces oxidative agents by 
oxidizing free radicals and is highly recommended in most cardioplegia. Hydroxethyl 
starch prevents shock based on blood loss. UW supplies have high costs especially from 
Organ-Recovery with a case of ten 1L bags. Other alternatives to decrease costs were 1-
2L samples from Bridge to Life Solutions Ltd (Columbia, SC) and CoStorSol™ sold 
under Preservation Solutions, Inc (Elkhorn, WI). Table 3.4 highlights and compares the 
two cardioplegia discussed by ionic values as well as an extracellular crystalloid solution 
that will be discussed in Section 3.3.  
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Table 3.4 – Ionic concentration comparisons of STHS, UW, and KHB 
[89, 99]
 
Cardioplegic solutions are supplied in 1L bags, with up to the full liter administrated 
to arrest the heart. Glutathione, insulin, and dexamethasone—an inflammatory 
inhibitor—are highly recommended as additives in whichever cardioplegia is used. 
Similarly, the extracellular HTK solution is similar to UW for short-term usage only 
[78]
. 
Intracellular solutions used for long term is Celsior, which is essentially modified UW 
solution. While UW sells on average at $230-$438 per liter, HTK (Custodiol) sells at 
$124-$211 per liter. Due to HTK’s viscosity, twice of the amount is flushed to 
compensate flow rate. Plegisol is the most cost-efficient and averages $90/L.  
Todo et al. 
[108]
 compared UW to varied extracellular solutions to preserve dog livers. 
80% of both subjects lived for more than 7 days. Comparisons between UW and other 
cardioplegia such as EuroCollins, Standford, and HTK solution shows  that highest 
content of ATP storage and best preservation of myocyte was due to UW solutions, in 
Schmidt et al. 
[116]
. A study by Wicomb et al. 
[84]
 used rabbit hearts and mechanically 
arrested the heart via coronary perfusion with 15-25 mL either Plegisol or UW. Hearts 
were topically cooled in iced saline and immediately tested. Cardiac output (mL/g heart 
 










(mMol) Intracellular Extracellular 
Na
+
 5-15 150 120 30 142.5 
K
+





 2.5 1.2 - 1.76 
Mg
2+
 - - 16 5 1.2 
H2PO4 - - - 25 1.2 
SO4 - - - 5 1.2 
HCO3 - - 10 - 25 
pH - - 7.8 7.4 7.4 
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wt/min) for Plegisol was 20.5 and UW at 34.7. When cardioplegia was applied for 4 
hours of cardioplegia, cardiac output was the following: Plegisol at 17.4, UW at 25.2 
[84] 
.   
A study by Lareau et al. investigated % recovery by developed force between 4⁰C 
and 12⁰C at 24 hours. Plegisol had higher recovery at both temperatures, with 110± 17% 
recovery at 12⁰C, UW at 32± 10% [117]. UW and STHS in prolonged ischemic 
comparison of 12 and 24 hours showed that UW was ultimately the better preservation 
solution as right ventricular systolic pressure was 125.6% versus STHS being 65.5%. 
Post-ischemic recovery of left ventricular rate of pressure increased as well as myocardial 
preservation had also improved due to UW 
[79]
. STHS had better myocardial recovery at 
tepid temperature than UW solution 
[112]
.  
UW solution offers more than the simple electrolytes that Plegisol does such as 
glutathione and allopurinol to limit oxygen radical injuries and decrease reperfusion 
injury; hydroxyethyl starch, lactobionate, raffinose limit edema. Adenosine has 
cardioprotective effects in aiding phosphorylation potential converting stored ADP to 
ATP 
[12]
. Even though they’re shown for long-term effects, the short-term effect from the 
link above showed higher cardiac output with UW. UW solution however impairs EDHF 
(endothelium derived-hyperpolarizing factor) function in porcine or human coronary 
arteries in which EDHF hyperpolarizes endothelium cells to vasodilate; As hyperkalemic 
cardioplegia initiates depolarization, hyperpolarizing cardioplegia with K+ channel 
openers are suggested. Mg
2+
 preserves EDHF relaxation and restores hyperkalemia 
impairment 
[87]
. Though most literature were based on long-term storage of ≥4 hours, the 
procedure developed in the thesis had 1-2 hour storage. When choosing cardioplegia, 
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long-term studies didn’t apply and ultimately was chosen on cost-effectiveness and 
efficiency. Static Plegisol was employed as cardioplegia, with UW solution used for 
transport towards the first half of tests and Plegisol used for the latter half of tests.  
3.2  Heparin and Streptokinase 
 
  To effectively wash out blood, heparin is used and recommended in studies with any 
blood usage, either in the animal’s circulation or in topical wash to prevent coagulation 
[13, 37, 39, 42-44, 46, 57, 75, 118-120]
. Many studies use only 5,000 U/L heparin in either 
cardioplegia or blood-based reperfusion 
[13, 43, 64, 75]
. Other studies use 10,000-25,000 U/L 
or  300U/kg of tissue weight for isolated hearts of several species 
[30, 37, 41, 42, 72, 73, 84, 94]
. 
However, as heparin causes for preventative measure, the drug does not affect formed 
thrombi. Instead of increasing heparin dosage, thrombolytic agents were looked at, 
specifically Streptokinase.  
Streptokinase (SK) has a high affinity to human plasmin and is immunogenic 
[109]
. 
Cost-effective and efficient, the medicine is the only thrombolytic drug listed in the 
World Health Organization List of Essential Medicines 
[104]
. The drug is a white, 
lyophilized sterile powder. As powder, the drug can be stored below 25⁰C and at -20⁰C 
for prolonged storage time, ranging from weeks to months. Once induced into a serum 
and reconstituted by saline or dextrose, it can be stored at 4-10⁰C for a maximum of 8 
hours only 
[103]






Figure 3.2.1 – Coagulation pathways of plasma factors. 
[121]
 
These thrombolytic agents are fixed protocols for treatment of acute myocardial 
infarctions (AMI) and embolisms and are activated by tissue plasminogen activator 
(tPA). Plasmin is an active enzyme that when active in the blood, degrades fibrin, a 
protein used in blood clotting. The proenzyme preceding the active plasmin is the 
inactive plasminogen, which activates in the presence of tPA, or naturally in the body by 
kallikrein and factor XII as diagramed in Figure 3.2.1. Plasminogen cleaving occurs at 
the Arg-Val amine bond, forming plasmin that breaks fibrin from thrombin. 
  Enzymes optimally perform at regular warm-body temperature of 37.5⁰C and 
exponentially decrease during hypothermia. Similar effects occur for pH, with optimal 




       
Figure 3.2.2 – Temperature (left) & pH (right) influences enzymatic activity. 
[122] 
 
  Pharmaceutical agents in 4⁰C solution have a minimal reaction as that is regarded as 
storage temperature. Although used in several studies and is recommended for 
experiments with blood usage, the anticoagulant Heparin was not used in our studies. 
Increasing cardioplegic temperature from 4⁰C to 20⁰C enables higher reaction rates of 
SK with clots dissolved 2 minutes after administration. Though optimal temperature of 
cardioplegia has 97% recovery at 4-10⁰C, cardioplegia at 20⁰C was at 88% recovery [112]. 





Intravenous infusion 1,500,000 IU/60 min 
Intracoronary infusion 
20,000 IU (bolus) 
2,000-4,000 IU/min for 30-90 min 
(60 min average) 
  For AMI, Intracoronary infusion is administered into the target coronary artery via 
coronary catheterization
[6] 
, seen in Table 3.5. The listed doses are for clinical and patient 
application only and not for the isolated heart. Streptokinase is also widely used for 
pulmonary embolism, deep vein thrombosis, arterial thrombosis—each with its own set 
of dose and duration for treatment. Heparin should be administrated prior to SK during 





 Streptokinase literature was reviewed to determine a concentration of streptokinase in 
an organ of similar mass and flow rate of the heart. Austrian’s G. Stark’s 1988 abstract 
discussed 2500U SK concentration/100 mL influencing the conduction circuit of the in 
vitro heart. SK resulted in a faster sinus node recovery time and ventricular border 
frequency and atrial border frequency had increased 
[106]
 . Mickelson’s 1988 study had of 
rabbit myocardial function protected by 150 U/mL Streptokinase in KHB, preserving left 
ventricular function and prevented increasing LVEDP 
[67]
. Mumme 1993 investigated 
temperature-dependent fibrinolytic activity for optimal temperatures of SK-induced 
cardioplegia. Fibrinolytic activity was 100% at 40⁰C and 7.9% at 25⁰C [96]. Hachenberg 
2001 investigated non-heart-beating livers that were preflushed with streptokinase at 
7,500U in 20 mL Ringer’s solution (concentration of 375,000 U/L) 
[62]
. Structural 
integrity was improved as metabolism recovered for efficient cardiac function.  Szyrach 
2011 had warm ischemic porcine kidneys preflushed with streptokinase, with Group C 
being administered 12,500 U/L and Group D at 50,000 U/L. Group D resulted in toxic 
effects 
[76]
. A study most similar to the research of this thesis was Mownah 2014 on 
reanimated porcine heart with 375,000U SK introduced into 250 mL AQIX 
(concentration of 1.5MU/L) 
[68]
. Limited peer-reviewed articles of streptokinase 
application on isolated organs were found. Based on the results of SK dosages from both 
isolated organ studies and patient in-vivo studies, the dosage of SK was determined for 
University of Denver’s isolated Langendorff study. The studies listed above show that 
concentration may vary and is not a factor on an isolated heart compared to a patient in 
which SK therapy can lead to tissue injury. In University of Denver’s testing, 20,000 U 
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on average is applied in 1-L cardioplegia, determined by the heart’s coronary artery flow 
rate of 225 mL/min to not induce high-pressure tissue injury.  
3.3  Krebs-Henseleit Buffer 
  Krebs Henseleit Buffer (KHB) is a physiological solution that increases and stabilizes 
metabolism from the cardioplegic effects 
[13, 37, 39, 42, 44, 46, 48, 57, 123]
. Though heparinized 
blood or red blood cells reconstituted in saline are preferable due to hemoglobin 
utilization for oxygen consumption and are performed in majority of Langendorff-based 
studies, saline-based solutions are investigated due to cost-efficiency and transparency to 
observe mechanical cardiac functions 
[14, 35]
. Mimicking blood, the buffer is generally 
composed of oxygen, salts, glucose, principle ions involved in initiating action potential  
(potassium, sodium, calcium, chloride) and other additives at one’s own preference that 
must follow a pH of 7.4 when oxygenated at physiological temperature 
[123]
. Buffer 
preparation provided by the manufacturer recommends 3.12 mMol CaCl2
 
which exceeds 
physiological level of 2.5 mM. The perfusate’s ionized calcium utilized in the procedure 
on average was half the value of physiological protein-bound calcium at 1.2 mM. 
Glucose is increased to 11 mMol/L as opposed to the normal in vivo 3-6 mMol/L range to 
compensate for lack of fatty acids in KHB as explained in Section 2.1. Insulin is 
recommended for heightened myocardial metabolism increasing developed pressure
[13]
. 
Due to the transparency, crystalloid buffers are best for video and camera footage of 




Table 3.6 – Comparison of studies with KHB usage, with or without blood mixture. A 
supplemental comparison of modified KHB found from additional literature 
review can be found in Appendix A. 
Author 
Rosenstrauch 










































NaCl 118.1 mM 118 mM 118.5 mM 118.5 mM 118.1 mM 
NaHCO3 25.0 mM 25.0 mM 25.0 mM 25.0 mM 25.0 mM 
KCl 4.69 mM 4.5 mM 3-4 mM 4.7 mM 4.7 mM 
MgSO4 1.17 mM 0 1.2 mM 1.2 mM 1.2 mM 
KH2PO4 1.17 mM 0 1.2 mM 1.2 mM 1.2 mM 
Glucose 11.1 mM 11 mM 5.5 mM 11 mM 11 mM 
CaCl2 2.54 mM 1.25 mM 1.2 mM 1.2-1.8 mM 1.5-2.5 mM 
Mannitol - 16 mM - - 16 mM 
pH 7.4 7.4 7.4 7.4 7.4 
1L of KHB was prepared by adding 9.6g of Krebs Henseleit powder (Sigma-Aldrich, 
St. Louis, MO; Product Number K3753) to 900mL Millipore water. CaCl2 was added, 
ranging from 1-3.12 mMol as listed in Table 3.7 (Sigma-Aldrich, Product Number: 
C7902-500G) prior to the addition of 2.1g Sodium Bicarbonate (Sigma-Aldrich, Product 
Number S5761-500G). All buffers were refrigerated prior to use. Any necessary buffer 
additives were mixed during magnetic stirring before Millipore water was added to 
complete 1L. All perfusates were delivered at 37-35.7⁰C and gassed with 95% Oxygen 
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and 5% Carbon dioxide. Table 3.6 notes the comparisons regarding core ions within the 
solutions of each study, with the majority of values being exact across studies. 
Manageable and cost-effective, KHB was the selected buffer for the DU Langendorff 
study and procedure, with variable calcium amount. The following section elaborates 
each section of the procedure.  
3.4  Procedure 
3.4.1  Slaughterhouse Harvest 
 Hearts harvested and used for this study (26 total hearts) were obtained from 
Yorkshire, Berkshire, and Hampshire pigs (136 kg ± 18.14 kg) that were slaughtered for 
human consumption. Hearts were isolated immediately after brain death via captive bolt 
pistol with brain stem intact to allow uninterrupted blood circulation prior to 
exsanguination. Sternotomy was performed under USDA protocol. Before access to the 
heart, the pericardium was inspected immediate to excision by a USDA officer for 
conditions such as tapeworms and tumors. WIT ranged from 90 seconds – 8 minutes 
between exsanguination to complete cardiac arrest via cardioplegia, decreasing in length 
of time over the course of the research due to slaughterhouse accommodations. Brief yet 
strict observance was undertaken prior to cold saline submergence so that the heart was 
actively contracting to accept the heart as a reliable test subject in which necrosis hasn’t 
taken effect 
[20] 




Figure 3.3.1 – Cannulated tubing structure to connect syringe for retrograde coronary 
flow towards the aorta. 1/3” diameter tubing for syringe insert was connected to ¾” to ½” 
transition cannula which was further connected to ¾” cannula that was secured into the 
aorta. 
3.4.2  Preservation 
  Given the heart-lung block, the heart was excised from the lung with aorta trimmed to 
2 inches and immediately cooled in a 4⁰C saline bath (Phosphate Buffered Saline tablets 
in aqueous solution, Research Products International Corp., Prospect, IL; Product 
Number P32080-100T) as blood was washed out and cardioplegia cannula was prepared 
to the aorta secured by string and zipties.  As application of any solution via aortic root 
starts, aortic valve must be checked to visualize that it is shut, intact, and in no way 
compromised. 1L STHS (Plegisol; Hospira, Inc, Lake Forest, IL) was poured into a 1L 
beaker as cardioplegia was applied using a 60-mL syringe via aortic root by a makeshift 
tubing system. The cannulated device was composed of a ¾” cannula held and secured to 
the aortic tissue by string, zipties and clamps to ensure backflow didn’t occur as seen in 
Figure 3.3.1. A total of 13 tests were accomplished with two subject hearts per 
experiment. For the first 6 tests, the antithrombotic method used 5KU-15KU/L Heparin 
Sodium Injection, USP (Sagent ™ Pharmaceuticals, Schaumburg, IL. Product Number: 
NAPPLA6K23D4, Lot Number: WJ3138N) during cardioplegic administration. 
Streptokinase was applied as antithrombotic agent for Tests 6-13 (Sigma-Aldrich, St. 
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Louis, MO, Product Number: S3134-50KU). As dosage on an isolated heart was 
independent of concentration, 10KU–25 KU Streptokinase was used per heart 
reconstituted in 500ml–1L 25⁰C Plegisol per heart. The tubing device was used for Tests 
1–10. Tests 11–13  replaced the cannula-insert device with Medtronic perfusion cannulae 
coronary catheterization (Medtronic Inc., Minneapolis, MN) lodged into the left and right 
coronary ostia (Figure 3.3.2), sealed by balloon inflates to direct 1-way flow, bypassing 
the aortic valve. Catheterization harnessed Medtronic DLP ®
 
Multiple Perfusion Set 
(Model Number 14007) and DLP®/Gundry ® Retrograde Coronary Sinus Perfusion 
cannula with manual-Inflate Cuff (Model Number 94615). 
 
Figure 3.3.2 – Superior view of the aortic valve closed under 72 mmHg. Perfusion was 
rerouted through coronary ostia and into the arteries.  
 Amount of air in the manual-Inflate cuff was determined by insert or outtake of air 
via 3-ml syringe from the inflation assembly with female slip luer and one-way valve 
(blue air chamber) as seen in Figure 3.3.3. Guide wires seen in Figure 3.3.4 directed the 
catheter past the ostia. Procedure was repeated for the second heart.  
Left coronary artery (left) Right coronary artery (right) 
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  The hearts were stored in an airtight plastic bag, each immersed in either 1L Plegisol 
or UW solution and placed on ice for hypothermic protection. Transportation was 60-130 
minutes in cold static ischemia, 70 minutes on average. UW solution was originally used 
as transport solution for the first half of experiments to implement the cardioprotective 
effects as found in Section 3.1.2. Based on cost-efficiency, Plegisol enacted as the 
dominant transport solution. In Test 4, to enable results similar to continuous perfusion 
than static storage, hearts were reperfused with 500 mL cardioplegia 30 minutes into 
transport.  
3.4.3  Resuscitation 
3.4.3.1 Water purification and pH 
  The Millipore system (Direct-Q® 3 UV with Pump Water Purification System, EMD 
Millipore, Billerica, MA; Serial Number F5MN93607E) was operational with 18 MΩ-ch 
Figure 3.3.4 – DLP®/Gundry ® 
Retrograde Coronary Sinus Perfusion 
cannula with manual-Inflate Cuff. 
Figure 3.3.3 – Medtronic DLP ® 
Multiple Perfusion Set. 
62 
 
being the highest filtration via 0.2μm absolute final filter and used by Test 3 to ultra-
purify tap water. Water used prior was DI water. Intermittent measurements were taken 
by Oakton pH/Conductivity/Temperature meter (Eutech Instruments, Singapore; Product 
Number 54X002608). Water quality not only stayed consistent but pH of KHB used for 
experimental purposes no longer needed HCl for adjustment and was consistent at a pH 
of 7.46 ±0.03 once oxygenated at room temperature by Test 2.  
3.4.3.2 Reperfusion 
  The Langendorff apparatus is an ex vivo circulation to introduce flow to the cardiac 
aortic root with the schematic found in Figure 3.3.5.  The aerated glass reservoir (HSE 
Glass Perfusate Reservoir for use with Peristaltic Pumps, Harvard Apparatus, Holliston, 
MA, Item Number 730322) contains 5L modified KHB (Sigma-Aldrich, St. Louis, MO), 
with 37⁰C buffer sustained by the heat exchanger pumped through the water 
thermocirculator. Oxygenation was 95% Oxygen 5% Carbon Dioxide, Carbogen, 
supplied at 9psi (General Air Service & Supply, Denver, CO, Serial Number: 
2201299RS).  ¼ inch and 10 mm Tygon 2375 tubing allowed oxygenated crystalloid 
buffer flow pumped by a second roller pump (Masterflex® L/S ™ Easy-Load® II; Model 
Number 77200-62). The heart lays within a chamber at a height of 45cm for added 
pressure column. A transfer cannula was inserted into the cardiac aorta and clamped in a 
homemade acrylic chamber. Exhausted buffer exited the heart into the chamber, 
collecting back into the reservoir.  An additional 2L were used for rewarming purposes at 
15⁰C and 25⁰C, sequentially, to prevent temperature-shock and reperfusion tissue-injury. 
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Infrared Thermometer (EtekCity ETC8380) measured temperature of the organ 
intermittently throughout testing. 
 
Figure 3.3.5 – DU Cardiac Langendorff constant flow schematic in Test 1-2. 
 




Modifications in KHB over the course of the experiments required the components 
found in Table 3.7. 
Table 3.7 – University of Denver’s Cardiac Biomechanics Lab Modified KHB (Sigma-
Aldrich ® Products K3753, C7902-500G, S5761-500G, and M4125-100G) 
Component Amount 
NaCl 118.1 mM 
NaHCO3 25.0 mM 
KCl 4.7 mM 
MgSO4 1.2 mM 
KH2PO4 1.2 mM 
D-Glucose 11 mM 
CaCl2 1-3.12 mM 
pH 7.4 
Reperfusion type KHB 
Mannitol 16 mM 
Insulin 0.25 ml/L 
Epinephrine (1 mg:1 ml) 0.25 ml/L 
Oxygen 9 psi 
  Reconstituted KHB should not be used after 2 days as glucose deteriorates, increasing 
risk of bacterial contamination. Ultimately, KHB lowers in acidity and becomes a pH of 
6.8 after 7 days. After 1-hour transport, the water heater (10L Fisher Water Bath, Serial 
Number 928579, FisherScientific, Pittsburgh, PA) encompassing the perfusate reservoir 
was heated to roughly 45⁰C ± 5⁰C and kept the circulating KHB at 37⁰C so that it was 
available for immediate use once hearts were mounted. Additional set up took 5-20 
minutes, prolonging cold ischemic time. Though usage of cardioplegia allows hearts to 
stay preserved 4-6 hours, the study was aimed to keep minimal length of cold ischemia to 
roughly one hour in which included minimum transport time and preservation 
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application. The most recently-excised and preserved heart with the shortest cold 
ischemic time was cannulated to the Langendorff extracorporeal system with carbogen 
pressure at 9psi. The Langendorff apparatus over the course of the experiments was 
originally set up to constant flow at roughly 120 mmHg for Tests 1 and 2, with the 
schematic shown in Figure 3.3.5.  From Test 3 - 13, constant pressure mode was 
determined with aortic pressure averaging 82 ± 10 mmHg with the schematic shown in 
Figure 3.3.6. Retrograde aortic pressure was measured by a pressure transducer (Statys™, 
BDC Laboratories).  
Insulin (ProZinc ® protamine zinc recombinant human insulin, Boehringer 
Ingelheim, Ingelheim am Rhein, Germany) was administered for Tests 4-6 when UW 
solution was utilized as the transportation medium. Recommended rate is 10 U/L. 1 mL is 
equivalent to 40 U and with 7L reperfusion, 1.75 mL/heart was administered. Both hearts 
per test used the same circulating perfusion, risking oversaturation.  
Flow rate via speed pump was determined by 1 ml/g of heart muscle 
[35]
 and thus, 
flow rate was 175 - 300 mL/min under oxygenation. Pump settings determined the flow 
speed at a setting of 2-3. The flowrate was kept constant for all test subjects. Temperature 
must always be monitored and regulated; 37.5⁰C is optimal body temperature—too low 
temperature decreases contractility, and suppresses enzymatic activity, whereas ≥39⁰C 
and above can lead to tissue injury and causes burns. An air trap was highly 
recommended for lethal air emboli blocking flow and must be cleared out through the 
circulation. Monitoring was key as fluctuating levels of pressures, temperature, pH and 
ions was a sure sign of reperfusion-injury damage, calcium-overload, and can ensure 
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further damage. All components are significant to the aid and function of the heart though 
moderation in certain ions must be considered such as calcium which will be discussed in 
Section 5.2.  
3.4.4  Pacing and Defibrillation 
  All hearts underwent ventricular tachycardia prior to fibrillation in which hearts were 
then defibrillated using by ZOLL ® R-Series ALS manual external defibrillator and ECG 
(ZOLL, Chelmsford, MA) with spoon paddles to stabilize cardiac sinus rhythm. 5-7 
shocks were administrated with a minimum of 5 minutes in between at 10-20 J. 
Pacemaker rate was set to 100 ppm, output at 15 mA, and sensitivity at 2.5 mV. Once 
stabilized, second-hand Single-Chamber temporary pacemaker (Medtronic Inc., 
Minneapolis, MN) was used to augment and aid the impulse during pacing and 
monitoring. Epinephrine (1:1000 1mg/mL, Amphastar Pharmaceuticals, El Monte, CA, 
Lot Number DTO38J3)  or any other types of β-adrenergic agonists are recommended for 
injection prior to defibrillation at a rate of 0.5-1 mL of 1mg:1 mL every 3-5 minutes or 
intermittently 
[39, 48]
. As the agents are in sterile vials, blunt BD PrecisionGlide needles, 
21 G 1 ½ were used for withdrawing the medication. 
  Ventricular fibrillation (VFib) is easily induced in large mammalian hearts and can be 
initiated by reentrant tachycardia and other sources of cardiac arrhythmia. Episodes of 
reentry is involved when propagation fails after excitation of the heart, resulting in atrial 
fibrillation, atrial flutters, and ventricular tachycardia after such myocardial ischemia 
[124]
. 
With such occurrence which disables efficient contractility, a defibrillator must be used 
to reset the electrical impulse to regular beating rhythm. The defibrillator used in the 
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study is biphasic in which VF is ceased with a lower current 
[125]
. Typically, the ECG is 
measured from the surface of the body by placing two electrodes directly on the skin and 
reading the potential difference between it. An isolated heart will have epicardial ECGs 
differentiate from full-body ECG as resistance differs between each medium. The 
detected waveform features depend on the amount of cardiac tissue involved in the 
contraction, as well as the orientation of the electrode placement with respect to the heart. 
A number of different ECG lead configurations exist based on electrode location 
[22] 
.  
Pacing was vastly recommended, securing the SA node to initiate consistent heart 
rates. Isolated heart beats are below that of normal physiological rate 
[35]
. Though pacing 
does aid regulation in contractility, in an isolated heart, the organ will ultimately undergo 
necrosis, certain tissues at its current state undergoing global ischemia over time. Though 
the nodal cells are self-initiating, the specific rate of in-vivo impulses are implemented by 
the right vagus cranial nerve (CN X) 
[14]
. Pacing should not go over 30 minutes for a 
living patient nor ex vivo heart as burns can occur with transcutaneous pacing 
[125]
. Pig 
hearts that averaged 250g in weight were recommended to pace at 100-120 bpm 
[75, 85, 126]
. 
Cardiac performance increases with reperfusion time and studies show that peak 
performance and stabilization occurs 30-90 minutes, dependent upon the additives and 
composition of the perfusate 
[37, 39, 48]
. Equipment was washed using Alconox® (Alconox, 
Inc, White Beach, NY) and diluted bleach prior to air-dried sanitation.  
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Chapter 4: Results 
4.1 Overview of Experimental Work 
  Results were collected for all 13 experimental tests. The following results are 
organized by all tests in chronological order. With Test 1 serving as a baseline, each test 
was modified based off of the inadequate results of the preceding test. This thesis 
includes all experiments in chronological order with a simplified procedure included per 
test. Results and data are categorized with the respective test, as each test discusses 
results and suggestions for the following test. Key progression within each test was fine-
tuning the procedure as well as calcium concentration. WIT per test ultimately decreased. 
In the study, WIT was defined as the lack of oxygenated normothermic blood from swine 
exsanguination to a complete 1L 4⁰C antegrade cardioplegic flush. Test 10 was the 
introduction of <5 minutes WIT with the heart immediately submerged in 4⁰C saline 
slurry from excision.  
Table 4.1 is a summary of all tests, highlighting Langendorff mode, cardioplegic 
additives, and mean heart rate for all experiments. Table 4.1 illuminates the progress of 
all tests towards the final satisfactory results which meet stabilized and functional cardiac 
activity. Physiological cardiac activity was achieved at 1 hour minimum with global 
contractile function. After heart stabilization via defibrillation of 15-20J and epinephrine 
application, stabilized heart rates ranged 60 - 110 bpm for an hour; hearts were compliant 
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during the duration of the first hour of activity with rigor induced by edema at the 1 hour 
mark. Cardiac function was monitored by the ECG functions of the external defibrillator. 
ECG reports are available from Test 8 thereafter.  ECG readings specify prominent QRS 
complex predominantly accompanied by Polymorphic Ventricle Tachycardia (PVT) prior 
to fibrillation in which is commonly caused by myocardial ischemia. PVT has multiple 
ventricular foci in which resultant QRS complexes vary that prominently leads R waves 
onto the T wave and degenerates to ventricular fibrillation, otherwise known as the “‘R 
on T’ phenomenon. Torsades de Pointes (TdP) is a type of PVT in which QT intervals  
are prolonged 
[125]




Table 4.1 – Stabilized heart rate per experimented hearts. All hearts originally underwent 
atrial or ventricular fibrillation. As testing progressed, hearts stabilized in 




































1 CF H 1.2 52* 0 




3 CF H 1.2 54* 30 




5 CP H 1.2 AFib 0 




7 CP H 1.25 8 0 




9 CP H 1.25 86 VF 




11 CP H & SK 1.2 N/A 0 




13 CP SK 1.2 120 0 




15 CP SK 2.5 145 79 




17 CP SK 2.52 100 0 




19 CP SK 0.5 100-180 0 




21 CP SK 1.66 176 24 




23 CP SK 1.66 143 126 




25 CP SK 2 172 110 
  26 CP SK 2.5 150 92 
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  13 tests were run, each with 2 subjects (26 total hearts). Only in a specific test was a 
heart not viable for testing (Heart 16) due to inappropriate tissue excision. This section 
dictates the consistent procedure used with minor modifications for each test, discussing 
the significant results of each test, and concludes with modifications to be utilized for the 
next experiment. Results continued to improve as additional tests were conducted, 
increasing efficiency for certain procedures kept constant. Certain details not annotated in 
literature review had to be sought out via experimental testing to design and develop a 
working Langendorff platform that allowed ≥1 hour global resuscitation.  
4.1.1  Test 1: August 20, 2013 (Hearts 1, 2) 
  Hearts were washed topically with 2L 2⁰C saline with 1L 4⁰C Plegisol (STHS) 
flushed via aortic cannulation before stored in 1L 4⁰C UW in plastic bags with indirect 
ice contact. Procedure and overview results may be viewed in Table 4.2. Cold ischemic 
time averaged 67 minutes.  
  Table 4.2 – Procedure with modifications and results for Test 1 
Parameter Heart 1 Heart 2 
Warm Ischemic Time (min) 15 13 
Topical wash 2⁰C saline 2⁰C saline 
Cardioplegia Plegisol Plegisol 
Cardioplegia Additive 5KU Heparin 5KU Heparin 
Transport 4⁰C UW 4⁰C UW 
Flow technique cannula cannula 
Reperfusion mode (CF or CP) CF CF 
Krebs Henseleit Additives Epinephrine Epinephrine 
Calcium (mM) 1.2 1.2 
Resuscitated period (min) 17 14 
Average Hear Rate (bpm) 52 (appendage) 78 (appendage) 
  Langendorff setup was at constant pressure with gravity directed flowrate roughly 250 
ml/min. Heparin and epinephrine application was provided by literature review and 
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suggested by physicians. CaCl2 was modified in KHB to be half of the physiologically-
recommended 2.5 mMol found in literature review and thus added at 1.2 mMol (0.176g) 
per Liter. KHB composition may be reviewed in Section 3.3. Movement in right 
appendages only contracted rhythmically at 52 bpm and 78 respectively for Hearts 1 and 
2. No contractions were monitored in the left ventricle, atrium, or apex. Hearts were not 
compliant. Coronary emboli and thrombi were apparent in the vasculature despite heparin 
preflush. Figure 4.1a & b illustrates the general laboratory and procedural set-up. 
Dissolving coronary thrombi becomes priority to allow unobstructed perfusion flow.  
     
(a)              (b) 
Figure 4.1a & b – Heart 1 Langendorff set-up (a) Constant Pressure mode Langendorff 
set up with reservoir column raised roughly 80 cm above heart. (b) Heart applied via 
constant pressure Langendorff perfusion with cannula attached towards aorta for Heart 1. 
4.1.2 Test 2 – September 24, 2013 (Hearts 3, 4) 
Modifications to the general procedure (Table 4.3) include application of Medtronic 
Model 5348 pacemaker and rewarming immersion was first introduced at 20⁰C before 
aortic cannulation to the Langendorff system. Procedure was kept similar as Test 1 with 
the addition of pacing the heart in Async to initiate signal towards the SA node. 
Pacemaker settings were set at 100 bpm.  Oxygenation was at 5psi and flow rate 
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averaging 500 mL/min. Pacemaker lead was administered once atrial appendage 
contractions stabilized. Test 2 highlights as the first test with physical activity in a 
cardiac region. Contractions proceeded with superficial left ventricle contractions at 30 
bpm; global contraction did not occur. Modifications to alternate the constant pressure 
system into a constant flow system were reviewed for future testing.   Procedure and 
overview results may be viewed in Table 4.3.  Coronary thrombi and air embolism were 
still located and prioritized to remove for future testing.  
  Table 4.3 – Procedure with modifications and results for Test 2 
Parameter Heart 3 Heart 4 
Warm Ischemic Time (min) 9 8 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia Plegisol Plegisol 
Cardioplegia Additive 10KU Heparin 10KU Heparin 
Transport 4⁰C UW solution for 72 min 4⁰C UW solution for 72 min 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CF CF 
Krebs Henseleit Additives Epinephrine Epinephrine 
Calcium (mM) 1.2 1.2 
Resuscitated period (min) 10 5 
Average heart rate (bpm) 54 (appendage) N/A 
 
4.1.3  Test 3 – October 8, 2014 (Hearts 5, 6) 
Test 3 was the onset of Langendorff perfusion set from constant pressure to constant 
flow, which was maintained for all future testing. The conversion allowed a minimal risk 
of air emboli in coronary vasculature, overriding autoregulated shifts in perfusate 
volume.  Minor modifications include the initiation of immersing hearts in a 1L beaker 
bath in which increased hypothermic effect of Plegisol as previous tests had flushed 
Plegisol pass through the vasculature only once prior to disposal.  However, cold 
ischemic storage was 2 hours. No visual activity on contractile function was significant. 
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Pacemaker was not used. Future testing would shorten ischemic storage from 2 hours to 
60-80 minutes. Procedure and overview results may be viewed in Table 4.4.   
  Table 4.4 – Procedure with modifications and results for Test 3 
4.1.4  Test 4 – February 16, 2014 (Hearts 7, 8) 
  Modifications include new cold ischemic procedure and insulin addition to the 
recirculating 37⁰C KHB. For Test 4 only, intermittent flushing of 500mL UW solution 
occurred every 30 minutes between initial preservation flush and reperfusion 70 minutes 
after, mimicking continuous flow. However, no significant increase in contractile 
function occurred. Recombinant human insulin (ProZinc ®, Boehringer Ingelheim, 
Germany) served as an additional energy source. Procedure and overview results may be 
viewed in Table 4.5.   
Parameter Heart 5 Heart 6 
WIT (min) 7 5 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia Plegisol Plegisol 
Cardioplegia Additive 5 KU Heparin 5 KU Heparin 
Transport 4⁰C UW for 117 minutes 4⁰C UW for 117 minutes 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives Epinephrine Epinephrine 
Calcium (mM) 1.2 1.2 
Resuscitated period (min) - - 
Average heart rate (bpm) AFib - 
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  Table 4.5 – Procedure with modifications and results for Test 4 
Further inquiry looked into alternating Plegisol to another cardioplegic source. 
Subsequently, Plegisol specifications were reviewed and sodium bicarbonate was 
requested to activate certain additives to the solution, increasing pH to 7.4. Though it was 
assumed the sterilized Plegisol was 7.4, pH of the sterile solution was 3.4, causing 
detrimental effects on the isolated hearts. The pH of 3.4 explains the failure in 
preservation for all previous tests. 
4.1.5  Test 5 – May 6, 2014 (Hearts 9, 10) 
 From Test 5 thereafter, Plegisol was modified with 8.4% sodium bicarbonate to 
stabilize pH to 7.4 and was the key modification. 8.4% sodium bicarbonate buffer was 
formed by adding 0.84g sodium bicarbonate to 10 mL water; the buffer was then added to 
the sterile Plegisol. Heparin was increased based on similar isolated porcine studies 
[43]
. 
As heparin was in storage temperature of 4⁰C and administrated to 4⁰C STHS and not at 
a physiologic temperature, half-life exponentially increased, slowing enzymatic activity; 
combined with hypercoaguability 
[50, 55, 127]
 of swine blood, the low dose of heparin was 
Parameter Heart 7 Heart 8 
WIT (min) 9 6 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia 4⁰C Plegisol 4⁰C Plegisol 
Cardioplegia Additive 7.5KU heparin 7.5KU heparin 
Transport 4⁰C UW in 70 min 4⁰C UW in 70 min 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives 
1.75 ml insulin 
1.75 ml epinephrine 
1.75 ml insulin 
1.75 ml epinephrine 
Calcium (mM) 1.25 1.25 
Resuscitated period (min) 10 5 
Average heart rate (bpm) 8 10 
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insignificant.  Thrombi formation was evident in vasculature, as seen in Figure 4.2. 
Procedure and overview results may be viewed in Table 4.6.   
  Table 4.6 – Procedure with modifications and results for Test 5 
 
  
(a)              (b) 
Figure 4.2a & b – Buffer flow visualization for Test 5. (a) Coronary arteries indicate 
buffer flow in Test 5. However, other minor vessels closer towards the apex determine 
partially occluding thrombi. (b)  Heart 10 shows hypothermic tissue damage and scarring 
once oxygenated KHB flow was introduced. Heart had a shortened resuscitated period.  
Mean atrial contractions averaged 77 bpm as myocardial temperature reached 37⁰C 
although no apical contractions were seen. Significant right ventricle contractions were 
apparent, leading to a follow up of equally dividing flow between the two coronary ostia. 
Parameter Heart 9 Heart 10 
WIT (min) 8 7 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia Modified Plegisol Modified Plegisol 
Cardioplegia Additive 7.5KU heparin 7.5KU Heparin 
Transport 4⁰C in UW Solution 4⁰C in UW Solution 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives 
1.75 ml insulin, 
1.75 ml Epinephrine 
1.75 ml insulin, 
1.75 ml Epinephrine 
Calcium (mM) 1.25 1.25 
Resuscitated period (min) 40 20 
Average heart rate (bpm) 86 AFib 
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Thrombi and air emboli disintegration are looked upon for future testing, specifically a 
fibrinolytic pharmaceutical agent.  
4.1.6  Test 6 – July 8, 2014 (Hearts 11, 12) 
Primary modification was application of the fibrinolytic drug, Streptokinase. While 
Heparin was used as a preventative measure, Streptokinase treated coronary thrombi 
already formed. Based on previous tests, keeping the coronary vasculature clear of 
thrombi was crucial as flow would not reach near the apex. Isolated hearts were gently 
massaged in order to aid vasculature flow to lower risk of coronary thrombi formation. In 
Table 4.7, WIT was increased due to training of experimental procedures and may have 
caused detrimental effects with lack of immediate preservation. Streptokinase was shown 
to be highly effective though visual cues indicated thrombi near the apex. Similarly to 
prior testing, epinephrine was used as needed prior to pacing. Pacing was set to rapid 
atrium pacing using Medtronic Single-Chamber temporary pacemaker with output at 50-
70 mA, rate at 100 ppm, sensitivity at ASYNC with the pacing lead fed through the right 
atrium, on contact with the base of the right ventricle.  Procedure and overview results 
may be viewed in Table 4.7.    
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  Table 4.7 – Procedure with modifications and results for Test 6 
Following the test, Streptokinase was determined to not be as efficient due to 
environmental temperature being equivalent to storage temperature, rendering inactivity. 
Assessing biochemical foundations of the pharmaceutical agents, Streptokinase and 
heparin had little to none effect at 4⁰C compared to a more physiological temperature 
(Section 3.2). Dosage of Streptokinase was not a factor as dilutions in studies ranged 
from 2mL to 500mL (Section 3.2). For future testing, 20⁰C of 250-300 mL would be 
applied prior to the 4⁰C Plegisol flush, with storage solution still constant at 4⁰C. A 
longer period of rewarming over the course of 30 minutes to prevent temperature shock 
and a colloid agent to decrease osmotic swelling was likewise proposed for future testing.  
4.1.7  Test 7 – November 4, 2014 (Hearts 13, 14) 
Mannitol was the primary modification of Test 7 in order to lower edema as well as 
preflushing the hearts with Streptokinase and heparin in 25⁰C saline. Dosage of heparin 
and streptokinase (SK) were increased from the previous examination and titrated to tepid 
saline.  Streptokinase was diluted in 500 mL saline at room temperature per heart. Heart 
Parameter Heart 11 Heart 12 
Warm Ischemic Time (min) 15 13 
Topical wash 4⁰C Plegisol 4⁰C Plegisol 






Transport 4⁰C in UW solution 4⁰C in UW solution 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives 
2 ml insulin, 
Epinephrine 
4 ml insulin, 
Epinephrine 
Calcium (mM) 1.2 1.2 
Resuscitated period (min) 26 19 
Average heart rate (bpm) 50 65 
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13 was topically rinsed with tepid saline. The heart was massaged to prolong coaguability 
and increase kinetic activity. Warm SK/heparin-infused saline was applied in retrograde 
fashion via aortic root to slightly cool the heart and lower the metabolism in order to 
prevent ischemic shock
[20]
 as well as have the biologic enzymatic activity performing at 
near-optimal level in a physiological temperature. WIT was noted as the timeframe 
between swine concussion to 4⁰C cardioplegic application, including the tepid 
pharmacologic pretreatment. By 4⁰C cardioplegic flush, no thrombi was visible within 
the vasculature. A slow flush was utilized to minimalize risk of ischemic shock, then 
flushed briefly with 150-300 mL UW solution prior to storage within 1L Belzer UW 
solution (Bridge2Life, WI). However, UW was provided by solution already contacted 
with the heart and not sterilized; there was high risk of catabolites and blood cells re-
entering the vasculature. UW solution in retrograde flow provided internal contact within 
the vasculature as well as exterior myocardium contact and to resolve apical 
underperformance. Procedure was repeated for Heart 14. Overview results and procedure 
may be viewed in Table 4.8.    
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Table 4.8 – Procedure with modifications and results for Test 7 
Subsequently, UW solution was perfused as a way to mimic continuous perfusion:  
the temperature of an object in a cooler of ice does not reach 4⁰C and may remain above 
8°C in semi-submerged positions; the muscle mass at the apex is thick and likely required 
persistent flow in order to penetrate the entire tissue and facilitate diffusion of ion 
concentrations.  
 
Figure 4.3 – Buffer flow visualization for Test 7 of KHB within coronary arteries 
(Heart 13).  Vasculature had a bluish tint and more translucent appearance compared to 
an in vivo heart. 
Prior to buffer reperfusion, 2.62g/L Mannitol was added to the buffer. Test 7 
highlighted the decrease in flow speed to a trickle as the aortic cannula was mounted to 
Parameter Heart 13 Heart 14 
WIT (min) 8 11 
Topical wash 6⁰C saline 6⁰C saline 
Cardioplegia 4⁰C Modified Plegisol 4⁰C Modified Plegisol 
Cardioplegia Additive 
25KU SK, 7.5KU heparin in 
500 mL 25⁰C saline 
25KU SK, 7.5 heparin in 
500 mL 25⁰C saline 
Transport 4⁰C UW solution 4⁰C UW solution 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives 
Mannitol (2.92g/l), 1.1 ml 
epinephrine 
Mannitol (2.92g/l), 1.5 ml 
epinephrine 
Calcium (mM) 1.2 1.2 
Resuscitated period (min) 38 35 
Average heart rate (bpm) 75 30 
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the heart aorta to decrease risk of air emboli before flow rate was increased back to 200 
ml/min. KHB allowed the veins to appear transparent as thrombi was cleared, allowing 
no occluding flow, as seen in Figure 4.3. Once reperfused by KHB, right atrium 
displayed regular and stabilized contractions, circulated by the anterior coronary artery. 
However, the remaining regions of the heart bore no contractions which may signify a 
lack of signal transduction and/or dysfunctional ion balances precluding myocyte cell 
membrane potentials. Pacing was as needed with an output of 50-70 mA, rate of 100 
ppm, and sensitivity at ASYNC. Pacing method was done with the (-) lead clipped near 
the SA node (internal pacing) (-) and the other (+) near the apex instead of using a pacing 
wire. Pacing was determined at the immediate onset of contractile performance prior to 
atrial or ventricular tachycardia. The technique was updated from applying the pacemaker 
once cardiac activity ceased. Decreasing flow rate into a trickle while mounting was used 
for all future tests. Heparin and Streptokinase were effective agents and coronary 
vasculature coagulation was eliminated as an obstacle while edema and ventricular 
function continued.  
Post-experimentation, Dr. Ashok Babu, cardiac surgeon of Anschutz Medical 
Campus and Dr. Christopher Orton, veterinary cardiac surgeon of Colorado State 
University offered various insights into the isolated heart experimentation and 
recommendations on the procedure.  Similarly to heart transplantation procedures, 
hypothermia should be immediate for excised hearts undergoing contractions prior to 
cardioplegic application. The surgeons enforced the usage of streptokinase and heparin 
due to swine hypercoagulability 
[50]
. Pressure applied during cardioplegic flush can 
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enable leakage past the shut aortic valves. While not detrimental to the left ventricle, 
muscle compliancy was impacted. Overdistension should be prevented and thus for future 
tests, mitral valve was kept open as working heart mode would not be utilized. 
Overdistension of the ventricle will increase the oxygen demand and have a negative 
effect on contractility 
[39, 55]
. 
Cardioplegia-induced ischemia, contact with ice, and reperfusion of KH Buffer can 
all lead to edema, and surgeons do agree that mannitol or any other source of colloids be 
used for osmotic pressure. A defibrillator was highly recommended, due to history of 
fibrillation with every test ultimately leading to shortened reanimation length. With 
smaller mammalian hearts than pig hearts, a pacemaker at a high enough setting can 
initiate defibrillation onto the heart. Though the classic and most popular AED equipped 
in buildings for emergency usages was suggested and is cost-effective, the device 
automatically traces the ventricular fibrillation and management was not certain for 
manipulating energy output. Usual AED exert 120J onto the general human body. 10-30J 
was recommended for isolated hearts, a value similarly used for open heart surgery once 
blood is re-introduced. The heart should not be paced when during fibrillation but once 
stabilized and at a standstill 
[55]
.  
December 9, 2014 (Heart N/A) 
Though no hearts were collected on this day, attempts were futile as time-sensitive 
buffers and equipment were prepared, as well as activated Plegisol with SK reconstituted 
into solution and thus with a life of 8 hours. However, pigs underwent scalding rather 
than regular exsanguination based on livestock availability. Hearts obtained from scalded 
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pig would have underwent temperature of 56-60⁰C with a WIT of ≥ 15-30 minutes [128]; 
the concept was disregarded. Key results from the test was to have the SK reconstituted 
only once hearts were accessible and prior to excision. Blood-cardioplegia was suggested 
as it was most efficient than pure crystalloid cardioplegia, with 1:4 heparinized blood, 
although never utilized during the series of test.  
4.1.8  Test 8 – January 27, 2015 (Hearts 15, 16) 
  Prior to Test 8, defibrillation was inaccessible. Modification made was a defibrillator 
used prior to pacing for contractile stabilization. Factors tested was compliancy and 
contractile recovery based on preservation in saline vs. preservation in Plegisol. Though 
saline is the gold-standard for hypothermia and cardiac preservation, a direct comparison 
was sought for the effects. Heart 15 had saline storage while Heart 16 was stored 
Plegisol. Heart 16 was significantly compliant compared to Heart 15 during rewarming. 
5L KHB were prepared for circulation while 2L expired-KHB was used for rewarming 
purpose only to minimalize expired glucose effect in the vasculature. Calcium was 
increased from 1.5 mMol to 2.5 mMol to follow recommended literature dictating half 
the physiologic range. However, Ca
2+
 measurement was inaccessible to determine 
utilization rate and if the amount or lack thereof was a factor in the decrease in 
contraction stability. The increase in Ca
2+
 indicated no significant increase in stable 
contractile function. Calcium overload influencing ATP utilization was an inhibiting 
factor that the experimentation aims to resolve. Procedure and overview results may be 





 Table 4.9 – Procedure with modifications and results for Test 8 
 
    
(a)          (b) 
Figure 4.4a & b – Heart 15 ECGs. Key observance of definite course fibrillation 




Parameter Heart 15 Heart 16 
WIT (min) 7 7 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia 
500mL 20⁰C saline prior to 
500mL 4⁰C Modified 
Plegisol 
500mL 20⁰C saline prior to 
500mL 4⁰C Modified 
Plegisol 
Cardioplegia Additive 10K in 20⁰C saline 10K in 20⁰C saline 
Transport 4⁰C Saline 4⁰C Plegisol 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives Mannitol (2.92 g/L) Mannitol (2.92 g/L) 
Calcium (mM) 2.5 2.5 
Resuscitated period (min) 37 25 
Average heart rate (bpm) 79 150 
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    (a)            (b) 
Figure 4.5a & b – Heart 16 ECGs. (a) Ventricular fibrillation can be determined by 
the second inclined wave in the QRS portfolio. (b) ‘Normal’ stabilized heart rate ECG 
peaks. 
  With respect to the ECG curves, there was no activity in Heart 15. The ECG curves 
agreed well with observation that there was no muscle contraction in the heart. Heart 16 
was stable and displayed “Torsade de Pointes” which is a distinctive form of 
polymorphic ventricular tachycardia (VT) as seen in Figure 4.5b. The reperfusate 
solution possibly being hypomagnesemic was a possible factor in which magnesium level 
should be increased >2 mg/dl. Though SK did clear coronary vasculature, blood had 
coagulated within the inner cardiac chambers in the duration of Test 8.  
4.1.9  Test 9 – February 3, 2015 (Hearts 17, 18) 
A comparison between Plegisol and saline preservation was repeated (Heart 17 Plegisol, 
Heart 18 saline). For both hearts, from animal concussion to SK preflush averaged 3.5 
minutes of total WIT. Prior to mounting on the Langendorff circulation, Heart 17 was 
compliant. Both hearts fibrillated upon reperfusion (Figure 4.6a and Figure 4.7a). 
Defibrillation was applied at 10-50 J, shocks administrated 2-3 minutes apart until 
stabilization (Figure 4.6b and Figure 4.7b).  Heart 18 stabilized only to return to 
fibrillation before inactivity with HR ranging 12-65 on Lead II. Mitral valve was kept 
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open to prevent left ventricular overdistension into the chambers.  Procedure and 
overview results may be viewed in Table 4.10.  The acclimating range for defibrillation 
was significantly varied; for future testing, 20J shocks will strictly be administrated.   
  Table 4.10 – Procedure with modifications and results for Test 9 
 
         
      (a)            (b) 
Figure 4.6a & b – Heart 17 ECGs (a) Ventricular tachycardia at 216 bpm. 




Parameter Heart 17 Heart 18 
WIT (min) 8 8 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia 4⁰C Modified Plegisol 4⁰C Modified Plegisol 
Cardioplegia Additive 
SK in 20⁰C Plegisol 
preflush 
SK in 20⁰C saline preflush 
Transport 4⁰C Plegisol 4⁰C saline 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives 
1.25 mL epinephrine, 
Mannitol (2.92 g/L) 
1.25 mL epinephrine, 
Mannitol (2.92 g/L) 
Calcium (mM) 2.52 2.70 
Defibrillation 10-50J 10-50J 
Resuscitated period (min) 30 30 
Average heart rate (bpm) 100 60 
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(a)               (b) 
Figure 4.7a & b – Heart 18 ECGs. (a) Stabilized with global atrial contraction at HR 
112 bpm prior to pacing. (b) Prominent wide wave can be seen for Heart 18. Superficial 
right atrial contraction can only be seen however to produce this ECG reading. 
  Samples of KHB were taken to the local medical campus under observation of an 
Atomic Absorption Spectrometer (AAS) for samples ranging from fresh KHB to KHB at 
60 minutes to calculate calcium utilization over the course of the Langendorff testing. 
Results from the AAS would indicate if cardiac death was based on ionized calcium 
depletion. AAS test ran with 0.05 mL KHB sample titrated with 5mL LaCl3 in which it 
was diluted 101 times.  
Table 4.11 – KHB Calcium Utilization under observation of AAS 







 Based on Table 4.11, Calcium myocardial uptake had occurred, with 0.2 ± 0.1 
mg/minute utilized; calcium depletion was not a factor. Schechter et. al suggested that 
calcium should steadily increase to avoid toxic effects 
[80]
. Perfusion began with 0.46 
mMol ionized Ca
2+ [80]
. 0.8 mMol was recommended in order to have the system operate 





was 0.694 mMol/L Ca
2+ 
(1.94 mMol CaCl2). A slow increase of Ca
2+
 in reperfusate was 
proposed for future testing despite Duke’s study using blood and how pure crystalline 
solutions would differ. Another study with whole blood/KHB-diluted perfusion also 
showed calcium levels at time 0 at 0.45 mMol. After 15 minutes, calcium level increased 
to 1.16-1.3 mMol 
[75]
. In du Toit’s 1992 study on rat hearts, a low extracellular 
cardioplegic with calcium level at 0.75 mMol improved cardio output to 91.8%. 
Reperfusion medium contained 1.25 mMol CaCl2 
[129]
. 
4.1.10 Test 10 – February 17, 2015 (Hearts 19, 20) 
Highlight of Test 10 compared the effects of Ca
2+
 levels at 0.5mM/L gradually 
increasing in Heart 19 vs. 1.2 mM/L Ca
2+
 in Heart 20. The results based off the 6L KHB 
were compared against Duke University’s study 
[80]
. 10KU SK in 20⁰C cardioplegia was 
also assessed compared to previous tests using 20KU. Also, cardiac recovery and 
contractile function based on immediate hypothermia (Heart 19) was compared to 
recovery based on delaying hypothermia to ensure Streptokinase was effective at 20⁰C 
(Heart 20). Heart 19 was cannulated to the Langendorff system with oxygenated KHB at 
20⁰C instead of 37⁰C, preventing optimal function. Function recovered with temperature 
increased after 30 minutes of resuscitation. Heart 19 had limited contractility including 
appendage contraction displayed. The heart continuously underwent tachycardia at 150-
200 bpm despite defibrillation.  Procedure and overview results may be viewed in Table 




Table 4.12 – Procedure with modifications and results for Test 10 
Parameter Heart 19 Heart 20 
WIT (min) 2 3 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia 4⁰ Modified Plegisol 4⁰Modified Plegisol 
Cardioplegia Additive 10K SK in 4⁰C Plegisol 10K SK in 20⁰C Plegisol 
Transport 4⁰C Plegisol 4⁰C Plegisol 
Flow technique Aortic cannulation Aortic cannulation 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives Mannitol (2.92 g/L) Mannitol (2.92 g/L) 
Calcium (mM) 0.5 1.2 
Defibrillation 10-50J 10-50 J 
Resuscitated period (min) 45 30 
Average heart rate (bpm) 100 150 
 
 
Figure 4.8 – Heart 20 ECG. Course VF was visualized by the two peaks located in QRS 
wave. 
Compared to Test 9, blood clots decreased in post-resuscitation dissection. With 
10KU SK directed into each heart as opposed to the 20K-25K previously used, the 
dosage may not had been effective. For Heart 19, 10,000U Streptokinase at 4⁰C had no 
significant effect. Heart 19 resulted with limited contractile function more so than the 
appendage contraction displayed though the heart continuously underwent tachycardia at 
150-200 bpm despite defibrillation. Tepid SK-infused cardioplegia resulted in the highest 
global contractile function and was to be used for all other future testing. Emboli were 
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still consistent within coronary vasculature. Heart 19 was added to apparatus at 20⁰C and 
temperature wasn’t modified to 37⁰C until half hour later. Procedure included mounting 
the heart at starting flow rate of 100 mL/min to avoid reperfusion injury and 
incrementally increase to 300 mL/min. Investigation on how metabolites in Plegisol 
affected the hearts’ recovery was addressed and would be looked into for the following 
test. A Medtronic representative suggested that warm SK-infused cardioplegia would 
provide efficient results and that using a small-point needle will alleviate vasculature 
emboli.  Also, epinephrine or lidocaine was recommended for future testing; epinephrine 
had been used in Test 1-6 and Test 9 but not for Test 7, 8, and 10 as no positive effects 
were seen. For all future tests, 37⁰C buffer must be immediate prior to heart mounting.  
4.1.11 Test 11 – March 24, 2015 (Hearts 21, 22) 
  Test 11 compared 36⁰C saline washout (Heart 21) vs. 4⁰C saline (Heart 22) for higher 
cardiac recovery. The test was to compare the immediate cooling to stabilize and lower 
metabolism output on a cellular level or to keep the vessels dilated in warm saline for 
blood, metabolite, and air washout and pass easily from microvasculature in heart before 
cooling. Keeping the vessels dilated in warm saline would increase WIT. Both hearts 
were still beating when excised and topically bathed in saline. Heart 22 had 
hypercoagulation, higher resistance, enabling higher pressure during cardioplegic flush 
prior dilation in arteries due to flow compared to Heart 21. All visible blood in the 
vasculature was ultimately removed. However, Plegisol flush was recycled from the 
transport bag mixed with blood and tissue particulates instead of using fresh sterile 
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Plegisol; It was probable that biologic debris from the nonsterilized Plegisol rerouted 
back into the vasculature. Procedure and overview results may be viewed in Table 4.13.   
Table 4.13 – Procedure with modifications and results for Test 11 
Parameter Heart 21 Heart 22 
WIT (min) 3 4 
Topical wash 36⁰C saline 4⁰C saline 
Cardioplegia Plegisol Plegisol 
Cardioplegia Additive 20KU SK in 20⁰C 20KU SK in 20⁰C 
Transport 4⁰C 4⁰C 
Flow technique 
Aortic cannulation and 
catheterization 
Aortic cannulation and 
catheterization 
Reperfusion mode (CF or CP) CP CP 
Krebs Henseleit Additives Mannitol (2.92 g/L) 
5ml epinephrine, 
Mannitol (2.92 g/L) 
Calcium (mM) 1.66 1.66 
Defibrillation 10-30J 10-30 J 
Resuscitated period (min) 51 0 
Average heart rate (bpm) 75 0 
Average aortic pressure (mmHg) N/A 94.8 
  Heart 21 displayed global contractions during contact with warm saline wash. 
Appendages continued beating during the cold cardioplegic flush. Contractions indicated 
ATP usage, depleting its reservoir. Heart 21 was mounted first to the Langendorff 
system. All previous tests had the most recent heart excised to be the first heart tested on 
the Langendorff apparatus, decreasing cold ischemic time for the first heart, extending 
the cold ischemic time for the latter. With this change in chronologic order, both hearts 




   
Figure 4.9 – Pressure transducer utilized in Test11.  Figure 4.10 – catheterization via 
4 mm tubes inserted directly into coronary ostia. 
Heart 21 displayed the first observance of significant apical myocardial movement 
via fibrillation. However, aortic tissue for Heart 21 was trimmed, severing the ostia 
towards the Right Coronary Artery. Unable to use an aortic cannula, the aortic valve were 
sutured and the coronary arteries were directly catheterized though unstable (Figure 
4.10). Heart 22 was remarkably less compliant than Heart 21. Aortic pressure could not 
be determined as the Y-catheter tubing fluctuated for a reliable reading. Despite the 
catheters sutured into the ostia, back flow prevented normal flow rate into the coronary 
vasculature and thus no stable contractile function was observed for Heart 21. The 




Figure 4.11a & b – Heart 22 ECG. (a) Ventricular fibrillation ECG prior to shocking 
(Heart 22). (b) Stabilized bradycardia HR 21 bpm (Heart 22). 
Figure 4.11a & b above visualizes both VF with a HR of 283bpm and the onset of 
poor electrical conduction resulting in bradycardia in the heart within minutes. Cell death 
progressed via lack of ATP utilization with HR 21 bpm in Figure 4.11b. Calcium 
overload was a certain factor due to muscular rigor and onset of edema. Partial 




Figure 4.12 a & b – Heart 23 ECGs. (a) Aortic pressure mean data acquired.  
(b) Heavy resistance with decrease in pressure (Heart 22). 
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Aortic pressure for Heart 22 can be compared from start time at 3,217.0 seconds (53.6 
minutes) from Figure 4.12a to end time at roughly 77 minutes, or 7716.75 – 3217 seconds 
from Figure 4.12b. Average aortic pressure was 94.8, well in the normal physiologic 
pressure range of 80-120 mmHg. Figure 4.12b has pressure decreasing at a downward 
rate of becoming approximately 10% of its original pressure with a mean pressure of 
22.6mmHg.  
4.1.12 Test 12 – March 31, 2015 (Hearts 23, 24) 
  As Heart 21 was unable to be operated efficiently due to incision of the coronary ostia, 
warm vs. cold wash saline test was repeated along with finding changes dependent on 
metabolite washout in recycled Plegisol vs. fresh Plegisol. Similar to the previous 
experiment, Heart 23 underwent warm saline wash; Heart 24 had cold saline wash. No 
pacemaker was used after Heart 23 was defibrillated twice. Both hearts showed 
contractile performance for ≤60 minutes. Procedure & results are shown in Table 4.14.     
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 Table 4.14 – Procedure with modifications and results for Test 12 
Parameter Heart 23 Heart 24 
WIT (min) 3 4 
Topical wash 30⁰C saline 4⁰C saline 
Cardioplegia 
20⁰C Plegisol preceded by 4⁰C 
Plegisol 
20⁰C Plegisol preceded by 4⁰C 
Plegisol 
Cardioplegia Additive 20K SK in 20⁰C Plegisol 20K SK in 20⁰C Plegisol 
Transport 4⁰C Plegisol 4⁰C Plegisol 
Flow technique Aortic cannulation and catheterization 
Aortic cannulation and 
catheterization 
Reperfusion mode (CF or 
CP) 
CP CP 
Krebs Henseleit Additives 
Mannitol (2.92 g/L), 
2 ml epinephrine 
Mannitol (2.92 g/L), 
2 ml epinephrine 
Calcium (mM) 1.66 1.66 
Defibrillation 10-20J 10-20 J 
Resuscitated period (min) >60 >60 
Average heart rate (bpm) 126 58 
Average aortic pressure 
(mmHg) 
117.9 N/A 
  Modifications for Test 12 include Coronary catheterization (Medtronic) at the 
slaughterhouse and a KHB preflush via Langendorff circulation. Langendorff apparatus 
continued using an aortic cannula to mount the heart. Test 12 signified the first 
observance of right ventricle contractility over the left ventricle due to flow dispersion 
between direct left and right coronary catheterization. Average aortic pressure was 
117mmHg, well in the normal physiologic pressure range of 80-120 mmHg (Figure 
4.13). Catheterized perfusion of 200 mL was directed in an ostium before switching to 
perfusion in the other ostium. Both atrial contractions were stabilized.  
Loss of contractile function can result from necrosis, decrease in temperature, and 
obstructed flow in vasculature. Decreased heart activity was compensated by increasing 
perfusion temperature towards 37⁰C again. The following test would focus on keeping 
the lung block intact with the heart during cardioplegic flush as an additional source of 




Figure 4.13 – Heart 23 mean aortic pressure. 
4.1.13 Test 13 -- April 7, 2015 (Hearts 25, 26) 
  Test 13 was modified to keep the lung block intact with the heart during cold saline 
immersion. Balloon catheters with inflates induced antegrade flow towards right and left 
coronary artery via ostia simultaneously. 100 mL tepid SK-induced cardioplegia was then 
applied to the ostia one by one before excising lungs to allow direct Plegisol circulation 
and clear blood from the microvasculature. Preceding lung excision, both arteries were 
perfused concurrently. During single ostium-perfusion, topical washing and saline 
sterility was maintained. Workbench chamber where hearts were perfused and submerged 
in cold solution was intermittently changed and replenished with fresh saline to remove 
all contact with blood. Hearts stayed beating while flushed with tepid SK-induced 
cardioplegia with 4⁰C topical saline. The set up may be viewed in Figure 4.14. Procedure 
and results may be viewed in Table 4.15.   
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Table 4.15 – Procedure with modifications and results for Test 13 
Parameter Heart 25 Heart 26 
WIT (min) 1.5 3 
Topical wash 4⁰C saline 4⁰C saline 
Cardioplegia 
20⁰C Plegisol preceded by 4⁰C 
Plegisol 
20⁰C Plegisol preceded by 4⁰C 
Plegisol 
Cardioplegia Additive 20KU SK in 20⁰C Plegisol 20KU SK in 20⁰C Plegisol 
Transport 4⁰C Plegisol 4⁰C Plegisol 
Flow technique 
Aortic cannulation and 
catheterization 
Aortic cannulation and 
catheterization 
Reperfusion mode (CF or 
CP) 
CP CP 
Krebs Henseleit Additives 
4.5 mL epinephrine, 
Mannitol (2.92 g/L) 
4.5 mL epinephrine, 
Mannitol (2.92 g/L) 
Calcium (mM) 2 2.5 
Defibrillation 20J 20J 
Resuscitated period (min) 72 63 
Average heart rate (bpm) 110 92 
Average aortic pressure 101 95 
 
       
(a)            (b) 
Figure 4.14a & b – (a) Heart 25 Langendorff apparatus set up. (b) Anterior zoomed 
view of Langendorff apparatus and set-up for Heart 25 with emphasis on aortic cannulae 
placement.  
  Ionic calcium levels increased from 2.0 - 2.5 mMol prior to Heart 26 mounted on the 
apparatus. Valves were stitched together as access to the left ventricle was unnecessary 
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and to eliminate ventricular overdistension.  Mitral valve was kept open to eliminate 
additional pressure.  Heart 25 had the highest rate of compliancy compared to Hearts 1-
26;   Heart 26 had higher resistance. Test 13 enabled both hearts to act as two separate 
circuits, limiting risk of vessel occlusion and efficient buffer and gas delivery to both 
right and left myocardial chambers. Reentry heart activity of fibrillation affected Heart 25 
and 26.    Heart 25 marked the first observance where intermittent defibrillation had the 
heart stabilized to sinus rhythm without additional aid before pacemaker was applied; 
global myocardial contractions were observed and constant. Air embolism was 
successfully removed by the bubble trap. Single-chamber pacemaker with lead inserted 
into the right ventricular chamber was set at a rate of 100 ppm, output at 15 mA, and 
sensitivity at 2.5 mV. Under these settings, the pacemaker successfully augmented the 
pulse. Using the pacemaker, the heart rate was modified by rate setting manipulation, 
decreasing or increasing stable contractions.  
  




    
(a)               (b) 
Figure 4.16a & b – Heart 25 ECGs. (a) Stabilized ECG reading over a 15 minute 
period. (b) Ventricular tachycardia leading to fibrillation. 
     
(a) (b) 
Figure 4.17a & b – Heart 26 ECGs. (a) Ventricular tachycardia leading to 





Chapter 5: Discussion 
Over the duration for the development of the slaughterhouse porcine isolated 
Langendorff heart procedure, the lab had achieved a beating isolated heart using 
crystalloid solution with cardiac function restored, global contractions for 1 hour 
resuscitation, and sinus rhythm at 90-110 bpm. Buffers used for all preservation and 
resuscitation advancements were stabilized to pH 7.4. The final procedure was secured to 
use Plegisol only as both preservation and transportation solution. Test 13 achieved 
<95% global ventricular recovery and compliance. The procedure for the highest 
recovery entailed the excised slaughterhouse porcine heart with lung block intact. After 
verifying contractility occurrence, the heart was immediately submerged in 4⁰C saline to 
wash out blood as well as lower cardiac metabolic state. WIT was 2 - 3 minutes. Lungs 
and tissues were originally trimmed pre-cardioplegic treatment for Tests 1 - 12 before the 
last test and thereafter pulmonary tissue was trimmed after the flush with the aorta 
trimmed for access of cardioplegic application. 500 mL tepid Plegisol modified with 
NaHCO3 infused with 20KU Streptokinase was first applied through coronary ostia 
catheterization retrograde flow via aortic root and washed out blood and metabolic waste. 
1L cold Plegisol completed the preservation flush per heart. Hearts were each stored in 
1L 4⁰C modified Plegisol in plastic bags with indirect ice contact, leading to 1 hour cold 
ischemia during transport back to the lab. 2L modified KHB were used for slow 
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normothermic rewarming at 15⁰C and 25⁰C before the organ was cannulated to the 
Langendorff apparatus with a 5L modified KHB circulation at 37⁰C. Flow rate would be 
lowered to a trickle while mounting heart via aorta before the flow rate was increased to 
200 ml/min. The KHB composition may be viewed in Table 5.1. Mean aortic constant 
pressure was 101.3 ± 1.94 mmHg.  
Table 5.1 – Modified KHB per liter 
NaCl 118.1 mM 
NaHCO3 25.0 mM 
KCl 4.7 mM 
MgSO4 1.2 mM 
KH2PO4 1.2 mM 
D-Glucose 11 mM 
CaCl2 2 mM 
pH 7.4 
Reperfusion Method Retrograde with respect to Aorta 
Mannitol 16 mM 
Oxygenation 95% O2 and 5%CO2 
Oxygen Pressure 10 ± 1 psi 
 All hearts underwent ventricular tachycardia prior to fibrillation; hearts were 
defibrillated at 20 J/shock with 5-7 shocks applied intermittently with a 2-minute delay. 
Once stabilized, the heart was continuously paced and monitored. Objective of 
developing a Langendorff apparatus using a blood substitute for slaughterhouse porcine 
hearts was met with global myocardial contractions and apparent QRS complex in ECG 
output was paced at 100 bpm. Edema was procured at 1 hour of cardiac activity. The 
result of the procedure mimicking average in vivo heart function exemplifies resuscitation 
through the effect of hypothermia on metabolism.  
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5.1  Hypothermia and metabolism 
Hypothermia does not cease tissue metabolism but rather prolongs reaction rates of 
enzymatic activity including degradation. As enzymatic activity declines, the 
mitochondrial coenzyme used as an energy transfer knowns as Adenosine triphosphate 
(ATP) is depleted as its precursor Adenosine diphosphate (ADP) inhabits the cytoplasm 
instead of the mitochondria and thus leans away from homeostatic levels 
[12]
. 
Hypothermia, though delays general necrosis and can enable intracellular and 
extracellular edema, acidosis, and glucose utilization. Active pumps are suppressed and 
oxygen uptake decelerates so that reactions shift towards anaerobic needs.  Ischemia-
reperfusion injury is derived from anaerobic processes such as lactate acid formation due 
to inadequate oxygen, or oxidative stress from sudden onset of oxygen 
[14]
. Such injuries 
can also derive from calcium overloading and acidosis. Examples of oxidative stress are 
hydroxide radicals, superoxides, hydrogen peroxides, and peroxynitrites.  Oxygen stress 
can lead to alterations of proteins, DNA, and large molecules in select areas of the 
membrane. To alleviate oxidative stress, glutathione and allopurinol serve as antioxidants 
for stabilization. Glutathione decreases the toxic free radical effects. Radicals however do 
open potassium channels, increasing permeability for potassium so that repolarization for 
action potential occurs. Permeability shifts towards potassium and away from calcium; 
calcium channels stay closed, decreasing chances for calcium overload. Oxygen delivery 
must be consistent to decrease the risk of oxygen-related injury. Delivery output of 
oxygen and other ions are regulated by either constant pressure or constant flow 
perfusion mode. Factors such as temperature also influence metabolism. A temperature 
103 
 
study on Plegisol indicated that tepid solutions increased contractile function over 




Figure 5.1a & b – Logarithmic values displayed for metabolism of endothermic 
species with respect to temperature (1000/K) values where ln(B0) signifies mass-
normalized metabolic rates as function for the inverse of temperature. 
[92]
 
  Figure 5.1 refers to the rate of metabolic process dependent on environment, ranged 
from 1000/(3 to 3.8) Kelvin (60⁰C, 21.1⁰C, and 9.8⁰C respectively) for resting metabolic 
rate for warm-blooded organisms. Mammalian values average 39⁰C prior to overheating 
and heat strokes exceeding physiological temperature for humans at 37⁰C. As 
temperature decreases, oxygen consumption and uptake (VO2) too, decreases. Van’t Hoff 
equation dictates that VO2 will drop by 50% per every 10⁰C decrease in physiological 
temperature. Cardiac arrest via 4⁰C cardioplegia then enables 97% MVO2.  In Figure 5.2, 












Oxygen saturation is based on hemoglobin affinity for O2 in blood. Saline solutions 
replicate the physical saturation level by an increase in O2 pressure. Lower pH is an 
indicator of anaerobic glycolysis with the increase in H
+
 in circulation. However, 
metabolic changes serve a miniscule effect compared to the over pH of the buffer 
[13, 14]
 .  
Even the hypothermic process must be looked into as direct contact of ice without 
solution on an isolated heart can cause freeze damage and tissue injury to myocytes 
[131]
. 
The following statement from HemoLab was only one example of cooling the isolated 
organ with both ice and solution contact: 
“The root of the aorta was cross-clamped, and 1,000 mL of cold (4 °C) Plegisol was 
delivered antegrade to stop the heart. The heart was cooled externally with 4 °C 
normal saline solution. Once cardioplegia was achieved, the heart was flushed with 
1,000 mL of 4°C normal saline solution to remove potassium. Finally, the heart was 
excised, weighed, wrapped in a towel to avoid direct contact of heart tissue with ice, 
and placed in an insulated container filled with ice-cold saline solution. The cadaver of 




Another example was the procedure highlighted by the Texas Heart Institute:  
“The heart may be cooled in 2 ways: 
 Blood is cooled as it passes through the heart-lung machine. In turn, this 
cooled blood lowers body temperature when it reaches all of the body parts. 
 Cold salt-water (saline) is poured over the heart. 
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After cooling, the heart slows and stops. Injecting a special potassium solution into 
the heart can speed up this process and stop the heart completely. The heart is then 
safe from tissue injury for 2 to 4 hours.” 
[28]
 
  The literature provided from Texas Heart Institute and HemoLab’s work were just a 
few examples in which topical hypothermia was routine for cardiac transplantation. A 
factor driving resuscitation and normal-level metabolism was calcium.  
5.2  Calcium and Calcium Overload  
  Calcium enables contractions to occur via attachment to the troponin complex that 
allows myosin to bind to actin in the cardiomyocytes. Physiologically, total calcium 
concentration in human ranges at 1.4-2.7 mMol/L. The range further breaks down to 
plasma ranging 2.1-2.55 mMol/L and ionized calcium averaging 1.5 mMol/L 
[6]
. 
However, physiological proteins are bounded to calcium as well as ionized calcium in the 
plasma. Without these proteins available, calcium amount was cut in half. Calcium 
addition to the tested KHB was ranged 1.2-1.25 mMol/L from Test 1 to 7. A summary of 
the calcium levels for all tests may be reviewed in Table 4.1. Post-study, parameters for 
biochemical ranges indicated that pig calcium levels were higher than humans, as it 
ranged 1.78-2.9 mMol/L 
[53]
.  
The first 7 tests used the ionized value as it was expected only half the calcium level 
would be needed to eliminate the amount bound to protein. Further investigation proved 
that the total calcium concentration of 2.1-2.55 mMol/L was dissociated from calcium-
bound protein. Calcium was a particular factor that had to be thoroughly analyzed and 
monitored to prohibit calcium overloading effects. Overloading effect was experienced in 
the testing via edema production, and decrease of Calcium in the KHB, as referred to in 
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Table 4.11. By Testing 8 and 9, Ca
2+
 was at 2.5mMol/L but cardiac performances failed 
at immediate fibrillation. Further calcium was added to the buffer for the second heart for 
Test 9 (Heart 18) in the even that calcium from Heart 17 performance had decreased 
calcium concentration. However, the addition of the Defibrillator was not manifested 
optimally with only a few shocks administrated without training. The onset of Test 10 
was to reproduce Duke University 
[80]
 test with the recommendation of ionized calcium at 
0.4 mMol/L and raised to 0.8 mMol/L prior to stabilized performance. After dissuading 
results, comparisons to the Duke study were revised and Test 11 and 12 provided 
1.66mMol/L. By the last test, Heart 25 was submerged in KHB with 2 mMol/L and Heart 
26 to 2.5mMol/L, both with satisfactory cardiac performance.   
  Calcium overloading may occur are due to a variety of reasons, the main being edema, 







 in the cell draws water in due to ionic bonds and hydrogen polarity
[13]
. 
Hyperkalemic solution, in which extracellular Na
+
 is high, allows the sodium gradient 







 back extracellularly and increased Ca
2+
 are pumped inside the cell. KHB 
is an extracellular solution. Low potassium is unable to repolarize to send Ca
2+
 
extracellular and thus more Ca
2+




 pump and the 
sarcoplasmic reticulum. Reperfusion-induced myocardial injury via oxidative stress leads 
to mitochondrial permeability transition pore opening 
[107]
. Reperfusion injury enables 
inflammatory responses towards reactive oxygen species. The induced response may 
increase the myocardial injury 
[107]





and lactate formation. Oxidative stress on the isolated hearts was possible as oxygenation 
binding wasn’t as competent as in vivo nature with regards to red blood cells and will be 
discussed further in Section 6.1.1. Risk of edema was immediate, which is further 
explained in the following section.  
5.3  Edema 
  The rate of edema is valuable information that relates to cardiac function and 
ventricular compliance in which if edema rate is significant, coronary perfusion may 
increase in resistance and flow becomes obstructed, leading to depressed performance 
and contractility. Myocardial weight gain percentage can be deduced due to edema. 
Edema can be determined by pre-experiment heart weight and post-experiment heart 
weight (Wtstart and Wtend respectively) to indicate water content 
[13]
. With an inverse 
correlation to compliance as the distension of volume due to increased pressure as 
opposed to a distending force 
[132]
, elastance measurements in the form of Emax and Emin 
should be sought. Emin is the end-diastolic elastance and Emax is the end-systolic elastance 
when used with a three-element time-varying Windkessel model. The model includes 
arterial compliance and peripheral resistance during any given point of the cardiac cycle 
[13]
.  
  Calcium overloading can also causing edema 
[5, 6, 8, 13, 14, 55]
. Colloid or other oncotic 
agents can lower water accumulation, such as albumin and mannitol. Albumin—
otherwise known as Bovine Serum Albumin (BSA)—eliminates edema by binding to the 
endothelial glycocalyx, reducing capillary hydraulic conductivity. Poelzing et al.  
[127]
 
discussed edema in detail in which mannitol in the excised heart could diffuse into the 
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extracellular matrix; when mannitol accumulation in the extracellular compartment 
exceeded the vascular mannitol concentration, fluid gradient osmotically leaned towards 
extracellular space 
[127]
. Edema is without preventability, as it was triggered and advanced 
during every step of the procedure, from harvest to preservation, to resuscitation. With an 
osmotic increase in cellular volume, less ADP was produced, causing for lesser heart 
contractility. In the isolated test experiments, although mannitol was added at 2.62 
mMol/L per test and had prolonged edema onset, it ultimately set in by the 1 hour mark. 
For future studies, mannitol will be replaced by albumin.  
5.4  Limitations 
  Limitations with severe accountability included the inaccessibility of living animal 
donors under a well-controlled system. Limited by option, slaughterhouse porcine hearts 
were used. With fresh slaughtered porcine, there was still the advantage of removing the 
heart with manageable WIT kept under 5 minutes rather than have the ischemic and 
necrotized frozen hearts supplied to the lab. However, the average 72 minute transport 
time in lieu cold ischemic time can be decreased, if not eliminated altogether, by using 
beating-heart donor instead of slaughterhouse-harvested donor. With cardiac resuscitation 
platform being developed in the founding stage of University of Denver’s cardiac 
biomechanics lab, parameter measurements were limited. Though measurements for 
hemodynamic flow rates, internal pressures on chambers such as LVEDP, preload, 
afterload were inaccessible, the parameters are indispensable for the translation from 
Langendorff to four-chamber working heart mode.  
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Procedure in preservation tactics while at the abbatoir as well as rapid cannulation 
became efficient with practice and thus earlier stages of the experiments with longer WIT 
certainly had negative effects. Practice on such tactics on either 3D heart models or non-
fresh non-tested hearts should be necessarily. Equipment such as pressure transducer, 
defibrillation, ECGs were not established until Heart 13, and pressure transducer even 
later from Heart 19. Originally heart rate was determined visually until ECG access via 
defibrillator monitored all readings. Despite internal paddle spoons able to measure heart 
rate, these were held by hand and readings weren’t constant. Thus any friction made by 
the holder easily disrupted heart rate reading. ECG leads were used for constant 
measurement and recording but both ECG wire connection shared the same connection as 
the defibrillating spoons; both could not be operated simultaneously.  
  Assessment with data acquisition is commonly used as cardiac parameters such as 
pressure-volume curves and atrial inflow.  Left ventricular end-diastolic pressure 
(LVEDP) is a global indicator for cardiac activity. This pressure is the difference between 
end-systolic pressure (Psmax) and end-diastolic pressure (EDP): PLVdev= Psmax – EDP. 
Similar to tension and compression, the heart contraction (dP/dt), relaxation (–dP/dt), and 
ejection fraction also dictate the rate of cardiac recovery.  Other inconvenience included 
foam particulate production for all tests at an ample rate of the KHB being utilized for the 
heart. Protein and fatty acid interference on KHB is a viable factor and currently foam 
formation has been unresolved.  Foam may be eliminated by anti-foam agents, usage of a 






Figure 5.3 – Foam accumulation during experiments for Hearts 22 & 23. 
  Unlike the standard computational simulation that is easily accessible to modify, the 
DU Langendorff study collaborated with Innovative Food LLC’s slaughterhouse which 
was undermined by the slaughterhouse’s schedule. Though swine was harvested on 
Monday and Tuesdays, their hours are flexible—pigs may come in the morning only to 
be succeeded by cattle followed by alternating back to swine harvest, particularly hog 
scalding at the end of the day; numbers of swine harvest varied week by week and wasn’t 
always accessible. Scalding would occur for the last few pigs harvested and was not an 
option for the experiments. Due to the distance between lab and slaughterhouse resulting 
in an hour of driving, the opportunity of testing proved rigid. Windows of opportunity 
were missed at times resulting in better communications between company and lab. 
These are not isolated events—expanded time in transit due to external circumstances 




Chapter 6: Future Research Developments 
As the Langendorff method of cardiac resuscitation was an initial step towards a 
physiological function to serve as a platform for further investigative purposes, different 
fields of tests will be possible. WIT was strictly monitored as slaughterhouse 
authoritative procedures were inflexible. Hearts were inspected by USDA in which that 
insight would be harder to obtain if done within lab operatives. With an ex vivo platform, 
the length of experiments will be acute, with resuscitation lasting 4-6 hours if not 
continuously perfused with blood as it naturally occurs in the mammalian body, such as 
the properties of the Organ Care System, discussed further in Section 6.3.1. With such 
limitations annotated in the Langendorff apparatus as discussed in Chapter 5, DU’s 
research aims to eliminate limitations and outline more efficient methods that will enable 
the beating heart to serve as a platform for further testing and extend the resuscitated 
duration.  
6.1  Optional Pharmaceutical Additives to Langendorff System 
Many other agents and additional solution may be added to elongate and enhance 
current resuscitation time without compromising global contraction function. Under in 
vivo conditions, energy supplied to the heart may derive fully from fatty-acids prior to 
resorting to secondary substrates such as glucose 
[133]
. Studies show that Heparin, fatty-
acids, and moderations in calcium in a working heart configuration were utilized to 
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recover and stabilize cardiac function up to a minimum of 4 hours 
[14, 45, 67, 80, 133-135]
. 
However, with an aqueous solution, fatty-acids stress the isolated heart and are insoluble 
to crystalloid perfusion. Albumin can replace mannitol as a colloid agent, eliminating 
foam production. Potassium channel openers are also suggested to lessen risk of 
ischemic-injury and increase cardiac protection 
[14]
. KHB components should be freshly 
prepared in the lab itself instead of using store-bought KHB mix. Correspondents from 
University of Alberta 
[136, 137]
 recommended keeping the inactive components of KHB in 
stock, as well as diluting and adding substrates ei. glucose, palmitrate, and sodium 
bicarbonate prior to usage.   
The current procedure utilizes 5L KHB to examine two hearts in sequential order; the 
second heart tested was in contact with unfiltered soluble metabolic waste from the first 
heart. Modifications should include fresh modified KHB introduced to the apparatus in 
regards to the second heart tested: 3-5L per heart will replenish ionic concentrations as 
well as filter out catabolites from the previous heart. KHB was recommended to be 
vacuum filtrated. Filters sized 2µm fixed prior to the perfusate entering the oxygenated 
reservoir can eliminate large particles, tissue debris, toxins, and catabolites.  
Oxygen delivery will be further investigated to enhance global contractility so that the 
heart may serve as a platform beating longer than an hour. An increase in oxygen 
delivery may be satisfied by the addition of red blood cells or perfluorocarbons. Red 
blood cells maximize oxygen transport due to the protein hemoglobin. Up to four oxygen 
molecules are carried on a single hemoglobin unit 
[5, 6, 14]
. Based on its bi-concave shape 
and lack of nuclei, a single red blood cell can encompass greater quantities of 
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hemoglobin, specifically 280 million per cell 
[6]
. The release and carrying capacity of 
oxygen to a hemoglobin protein is dependent on increasing partial oxygen pressure (pO2). 
The addition of the natural proteins in blood would alleviate edema by increasing oncotic 
pressure; coronary flow rates would match physiological speeds. Even if blood is not 
used, red blood cells in KHB should be filtered as risk of shearing via roller pumps is 
high. Membrane oxygenators are required for blood use 
[35]
.  
Oxygen delivery was futile and less than efficient in KHB. Perfluorochemical or 
perfluorocarbon (PFC) enable twice as much pO2 carrying capacity in aqueous solutions 
and may be used as an additive to either the reperfusion or the cardioplegia to lower the 
risk of acute myocardial infarction (AMI) 
[35]
. PFCs have been implemented in a myriad 
of preclinical trials as a blood replacement oxygen carrier, where the literature reflects 
minor side-effects. PFCs are cost efficient, deliver ample oxygen at normal pressures, and 
prevent edema. For PFC to be soluble in aqueous solutions, an emulsion with surfactant 
is required. However, PFCs are not FDA approved and are currently under preclinical 
trials. PFCs are intended for ischemia zones attenuated from postischemic reperfusion 
injury and prevent ischemic contractures 
[91]
. Increasing oxygen delivery, sterile 
perfusion, and the directed pharmaceutical agents will allow and enhance the resuscitated 
heart to serve as a platform for an increased length of time. 
6.2  Four-chamber working heart 
  The Langendorff method can be converted into a four-chamber working heart system 
in which right and left chambers of the heart are synchronous in cardiac activity, 
conserving reperfusate in a closed-cycle. Similar to in vivo function, blood-filled atria 
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compress to empty blood into the ventricles, where each ventricle contracts to direct flow 
from the RV towards the pulmonary system and the LV to the aorta towards the systemic 
circulation, respectively. Preload and afterloads conditions must be prepared for optimal 
working heart function. The configuration requires higher energy usage, thus 
Langendorff perfusion should render cardiac resuscitation stabilized prior to the working 
heart mode. 
The four-chamber working heart perfusion enables complete usage of all chambers 
and musculature. Whereas retrograde flow of perfusate was the only route via aortic root 
in Langendorff, the working heart enables antegrade flow out of the left ventricle, past 
the open aortic valve; as the valve shuts, flow is then directed towards the coronary 
vasculature. Figure 6.2.2 illuminates the details of a working-heart system that will 
maximum myocardial performance and global contractile function. Valve activity is 
based on heart contractions and thus coronary flow is induced by a natural flow and not 
the roller pump originally used in Langendorff. Based on the Frank-Starling law, increase 
in preload regulates an increase in muscle contractions via higher chamber filling. 
Preloads and afterloads must be regulated by the apparatus. Afterload pressure is the 
resistance to the output ejected via diastolic aortic pressure and will increase cardiac 
output; however, both overdistention and hypotension can decrease flow and impair 
contractility. Higher preload and lesser afterload is optimal for a stable cardiac 
performance 
[35, 37]
. Ejection fraction and stroke volume can decline with the loading 
pressures reversed with a high afterload and low preload 
[37, 39]
. Global myocardial 
functions may be assessed by stroke volume and ejection fraction. The apparatus will be 
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designed to have Langendorff and Working Heart mode easily be converted from one to 
the other as shown in Figure 6.2.2. 





RA 2-10 mmHg 
LA 5-15 mmHg 
Afterload 
RV 10-20 mm Hg 
LV 70-110 mm Hg 
If 1 mmHg is equivalent to 1.13 cm of the reperfusion height column, aortic afterload 
must be almost a meter above the heart and be even greater in length if a hypertensive 
circulation is to be tested. An intraventricular balloon with a catheter attachment acts as a 
pressure transducer with an end-diastolic pressure of 5-10 mmHg as Table 6.1 indicates 
so that contractions are easily sustained. The balloon is inserted into the left ventricle via 
mitral valve; the left appendage may be removed if needed 
[35]
. The intraventricular 
balloon aids in preloading as it implements the Frank-Starling law (Section 1.4) while 
accurately measuring LVEDP, contractile function, and heart rate (Section 1.7) 
[13, 35]
. 
Passive filling of the atria will not determine elastance 
[37]
 and thus either a three-point 













6.3  Outreach for collaborations and human hearts 
Using the Langendorff configuration that converts to working heart configuration 
exemplifies further research purposes by becoming a platform to study specific 
physiology, histology, or mechanical interactions with certain medical devices. Currently, 
the DU Langendorff system is gaining attention with local clinics interested in 
investigating ablation therapy specifically to the right ventricle, in vivo flow 
measurements with MRI, and other medical testing and such therapies. Permission was 
obtained from Colorado Donor Network to use human donor hearts rendered unsuitable 
for transplants based on satisfactory results with respect to the procedure. Investigations 
on human hearts may be compared to porcine heart results.  
6.3.1 Mobile Langendorff/Working model for faster accessibility and usage 
As a single-heart-testing lab-stationed swine model leads to various complexities 
regarding ionic concentrations, metabolites, and whole cardiac function due to a 1-hour 
ischemic time, a mobile system would increase not only efficient resuscitation but extend 
the resuscitation period. To have a mobile system that could be brought into the 
slaughterhouse would eliminate transport time and by extension, cold ischemic time; the 
isolated organ would be continuously perfused with warm modified and oxygenated 
KHB, decreasing the amount of cardioplegic usage. Based on literature found in Section 
2.5.1 on varied cardioplegic solutions, warm-blood solution led to 70% functional 
recovery of left ventricle contractile function as opposed to 46% via cold blood solution 
[111]
. Increasing options for cardioplegic methods allow greater postischemic recovery. 
Other studies show similar reports with continuous warm cardioplegia such as the mobile 
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Organ Care System located in the following section (Section 6.3.1.1) with 80-93% 
LVEDP recovered. For such mobile systems to work, access to set up a station at either 
the slaughterhouse or in vehicle is required, including but not limited to oxygen tanks, 
refrigerated solutions that can easily be heated, a sterilized environment including 
electrical sources.  
  The proposed mobile device is similar to a product currently in clinical trials in the US 
and out in market in international countries. Transmedic Organ Care System: Heart ™ 
(OCS) utilizes continuous warm blood in pulsatile flow of an isolated donor heart. 
Produced in 2006, instead of hypothermia lowering the metabolism, the OCS 
continuously keeps the heart beating, ensuring the organ at 37⁰C and consistently 
monitors all physiologic activity as it is held in the device’s chamber
[100]
. The heart 
continues pumping oxygenated blood until transplanted 
[14]
. The OCS leads to net 
improvement compared to traditional transportation and reduces ischemic time. Using 
this new technology, hearts can now be transported for successful transplantation past a 
distance of 450 km (280 mi). Hearts may be transported past local junctions and towards 
densely populated cities; organs that are able to be preserved and not needed in isolated 
towns/countries can now be transplanted across water boundaries in which hasn’t been 
done before in the past. Not only does the pool of donor hearts increase in terms of 
location distribution but also hearts from non-beating donors can be utilized as well as 
beating-heart donors, including previously-diseased hearts for transplantation. Suggested 
increase in the amount of donor hearts is expected to be 25% in Europe alone 
[100, 140]
. 
Total cost of care will be reduced.  
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  The ‘box’ contains OCS monitors, cables, connectors, portable defibrillator, solution 
transport bags, iStat (ionic analyzer), Alaris infusion pump, pure oxygen cylinder, and 
filling buffers. The system’s internal memory records all equipment system error and 
alarm notifications for the heart rate though an SD memory card can be used. Updates are 
saved automatically every 15 minutes. To add to its accessibility, the box is mobile with 
wheels. Clinical testing was done in Padua, Italy under Dr. Gino Gerosa, as well as 
Austria and France; Select hospitals in the US have initiated clinical trials in 2015.  
 
Figure 6.3 – Resting Mode of TransMedic Organ Care System ™. 
  In the OCS studies, 1.2L blood was taken from the donor at the outlet of the aortic 
arch. 500mL-1L Plegisol was used as the cardioplegia. Defibrillation was set at 5J and 
occurs twice and 10 joules once. Catabolite removal hasn’t been secured in OCS until 
end of transport. However, TransMedic have established a membrane to attach to the 
interior of the heart walls itself in the OCS in which catabolites diffuses into a dialysis 
solution to purify the blood in the system cycle 
[100]
. The OCS enforces that mobile 
Langendorff resuscitation is futile and manageable, increasing the door for heart donors 
of cardiac transplantation.  
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Chapter 7: Conclusion 
A procedure conditioning the slaughterhouse porcine isolated Langendorff heart for 
resuscitation using a crystalloid buffer, stabilized global cardiac function, and compliance 
for 1 hour was achieved. 250-300g hearts were retrieved at the local slaughterhouse, with 
2-3 WIT. The lung-heart block was kept intact and was submerged in 4⁰C saline wash, 
which cleared blood and decreased metabolic temperature. 20KU Streptokinase in 500ml 
20⁰C modified Plegisol of pH 7.4 was antegrade flushed through the coronary arteries via 
coronary catheterization. Lung block was dissected prior to storage. Test subjects were 
stored in 4⁰C Plegisol with indirect ice contact under roughly 1 hour cold ischemic 
transport time as it was brought back to the lab.  5L of 37.5⁰C modified KHB with 2-2.5 
mMol calcium chloride dihyrdate served as the reperfusion buffer. Buffer was 
oxygenated at 9psi carbogen and pH was 7.4. Prior to cannulation to the Langendorff 
system, the hearts were normothermally raised in temperature at increments of 10⁰C per 7 
minutes. Langendorff mounting system was 45 cm high, under constant pressure with 
mean aortic constant pressure as 101.3 ± 1.94 mmHg. Air emboli were eliminated and 
constant ECG was monitored. At start of tachycardia for the mounted heart, ZOLL® 
defibrillator was applied at 20J per 5 minutes with induced epinephrine until stabilization 
and normalized heart rhythm. Heart rate averaged 90-110 bpm. At onset of stabilization, 
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internal pacing was commenced and augmented at 100 ppm, output at 15 mA, and 
sensitivity at 2.5 mV.  
This thesis breaks in piece, part by part of University of Denver’s two-year study 
from background, and preliminary studies which evidently set up the experimental 
materials and methods. Results from the 13 tests inspired discussion. An isolated ex-vivo 
slaughterhouse beating model was developed using Langendorff methods and can easily 
be converted to a four-chamber Working Heart Model. The beating model meets 
qualifications to serve as a model to mimic the physiological heart in which medical 
devices and therapies can be tested on to assess design conditions and improvement. 
Future works include the Langendorff system as a platform for quantitative flow dynamic 
testing for an implanted transcatheter aortic valve. The thesis written about the 
Langendorff model does not depict alternatives that were reviewed when determining a 
future step of action to modify the procedure. An array of over 200 literature was 
reviewed not only for the procedure modifications but as separate mini studies about 
smaller fields of the study, whether it be cardioplegia, temperature, pharmaceuticals, 
procedure, cost-effective alternatives, ordering equipment, and intricate detail that 
sometimes could not be found in literature. The experience of research in an 
interdisciplinary field was rich and there can only be progress made as the Langendorff 
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Appendix A: Modified Crystalloid Reperfusion Buffer 
The table provides additional crystalloid buffer comparisons to the DU Cardiac Lab preparation. The appendix is an extension of 
Table 3.6 but is by no means exhaustive. All reperfusates are oxygenated with pH 7.4 and temperature of 37⁰C. 
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Rats - Modified KHB 
CF 
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Rat 360-400 bpm Modified KHB 
CP 
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